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"Imagination is more important than knowledge. Knowledge is limited, whereas 
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I decided to become an oncologist on the fourth year of medical school, under the wings of 
Dr. Vera Tomé, a great oncologist who ended up being my mentor. At that time, I had no idea 
I would like to focus on the melanoma field. My inspiration? Two young mothers, both with 
advanced melanoma, brain metastases and both treated with temozolamide, but unfortunately 
died soon after, in my second year of residency. I will never forget them. At that time there 
were very few therapeutic strategies for melanoma and a lot of disappointing trials.  
I have always liked research, but I forgot that feeling for a few years when I fell in love with 
the clinical work and I mistakenly thought we could follow only one career, doctor or 
researcher. When I heard about the Programme for Advanced Medical Education, I saw it as a 
great opportunity to combine two passions, clinical work and research, and this way develop a 
real translational project. I had the invaluable support of my family and friends and I decided 
to apply to the Programme for Advanced Medical Education in 2009, a PhD program for 
medical doctors, sponsored by Fundação Calouste Gulbenkian, Fundação Champalimaud, 
Ministério da Saúde and Fundação para a Ciência e Tecnologia. The initial six months of the 
programme included classes and seminars on various topics, from basic science to 
translational research and epidemiology. The goal of this educational period was to provide 
the students with solid scientific basis in order to develop research projects oriented for 
specific clinical questions. 
The decision to interrupt my residency for 3 years to develop my research project was not an 
easy one to make, but seemed the best one for me at that time. The switch from a purely 
clinical thinking to an integrated clinical and scientific thinking was hard but in my opinion, 
completely essential in order to develop a good project. This decision allowed me to go 
abroad and join a renowned laboratory in the melanoma field. At that time I had little 
knowledge and experience regarding good laboratories and centers in melanoma, so I decided 
to search them. After a first selection of some laboratories and contacting them, I got three 
interviews. The first one at New York University (NYU), with Iman Osman, that went 
extremely well and made me feel at home right away. The second was at Memorial Sloan 
Kettering and it went also well. I was completely divided between these two excellent centers 
when I went to the third one at the Ludwig Institute in New York City. This interview was 
	  





with Dr. Lloyd Old, an impressive man and researcher, pionner in TNF blockade who asked 
me whether I wanted to study immunology by using melanoma as a model, or if I wanted to 
focus on melanoma through immunology pathways/immunotherapy. My answer was the latter 
and he immediately advised me to go to NYU and to work with Dr. Nina Bhardwaj and Dr. 
Iman Osman. I will be always grateful to Dr. Lloyd Old. I have never regretted my decision. 
During the first three years I worked in the Bhardwaj labortory and I have to highlight the 
extraordinary people I met there. Working with them allowed me to learn a wide variety of 
techniques and to become familiar with the latest technologies in the field. I was also able to 
establish different collaborations, within NYU and with other institutions, and to participate in 
the development of phase I trials using vaccines. After these three years, I had completed 
most of the work for my research project, and I was ready to go back home. At that time, 
unexpectedly, I was invited to stay one extra year for a clinical and research fellowship 
position in melanoma. I accepted it, did the United States Medical Licensing Examination 
(USMLE) exams and stayed. During that year, I managed to accompany melanoma patients, 
while doing clinical research, and I was able to finalize and develop some other projects.  
My overall experience in New York City exceeded my best expectations. Besides an amazing 
research experience, those four years were a milestone in my personal life. New York is just 
an extraordinary city with an overwhelming cultural life and everyone I met during this period 
made this experience even richer. Undoubtedly, this was one of the most important periods of 
my life that I tried to share with my family and friends, by writing a weekly newsletter that 
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Th T helper 
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TME Tumor microenvironment 
TNF-α Tumor necrosis factor alpha  
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TRIM Transmembrane adaptor T-cell receptor interacting molecule 
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Melanoma is the fifth most common cancer in men (seventh in women) and its incidence is 
increasing more rapidly than that of any other malignancy. It is the most aggressive type of 
skin cancer; although it accounts for 2% of all skin cancers it leads to more than 70% of their 
deaths. In fact, melanoma responds poorly to systemic therapy and the overall prognosis of 
patients with distant metastasized melanoma remains poor; the 2-year overall survival rate 
ranges from 18 to 40%.  
In the context of cancer two opposite immune responses exist: an acute T helper (Th) 1 anti-
tumoral response that requires a substantial autoimmune attack; and a pro-tumorigenic 
inflammatory response, characterized by an immune tolerance via active immunosuppressive 
mechanisms. During tumor progression there is an imbalance with a stronger pro-tumorigenic 
inflammatory response, while the anti-tumoral Th1 cells display a dysfunctional phenotype. 
The new concept of “T cell exhaustion”, that has been developped in the past few years, can 
explain T cell dysfunction. This “T cell exhaustion”, either caused by environmental influence 
or other factors, was first described in chronic infectious diseases and more recently in 
different types of cancer, particularly in melanoma. This phenotype is characterized by early 
loss of proliferative capacity, cytotoxic potential, and the ability to produce interleukin (IL)-2. 
The concept of T cell exhaustion in the context of metastatic cancer has been reinforced by 
the recent success of immunotherapies targeting the exhaustion markers cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4) and programmed (cell) death 1 (PD-1) in 
advanced melanoma. However, the phenotype and function of natural killer (NK) cells in 
different phases of tumor progression and their relationship with prognostic factors is still 
unknown.  
NK cells are innate immune cells, prone to target tumor cells, whose function depends on the 
balance between activating and inhibitory receptors, and on the expression of the respective 
ligands in their microenvironment. T cell immunoglobulin domain and mucin domain 3 (Tim-
3), another T cell exhaustion marker along with CTLA-4 and PD-1, behaves as an inhibitory 
receptor in T cells and is key in the maintenance of immune tolerance. Tim-3 is also 
expressed in NK cells; however its role in modulating the function of these innate effector 
cells remains unclear, particularly in human disease.  
	  





The aims of this study were: to characterize the phenotype and function of NK cells from 
melanoma patients; to identify potential players in the mechanism of NK cell exhaustion as 
prognostic markers; to define the role of Tim-3 expression in NK cells from advanced 
melanoma patients; and to study the effect of checkpoint blockade in NK cell phenotype and 
function in the context of advanced melanoma patients. 
Our data showed that NK cells from patients with advanced melanoma display an exhausted 
phenotype that is characterized by upregulation of inhibitory receptors (Killer cell 
Immunoglobulin-like receptor 3DL1 and 2DL3 - KIR3DL1 and KIR2DL3, respectively), 
downregulation of activating receptors (natural-killer group 2D (NKG2D), natural killer p46 
(NKp46) and DNAX accessory molecule-1 (DNAM-1)), unresponsiveness to IL-2 
stimulation, downregulation of the transcription factors T-box (T-bet) and eomesodermin 
(Eomes), and defective function. The latter includes the main NK cell functions, cytotoxicity, 
interferon gamma (IFN-γ) production and proliferation.  
NK cells acquire this exhausted phenotype gradually as disease advances from early (stages I 
and II) to later stages (stages III and IV). Moreover, the exhaustion of NK cells is associated 
with clinicopathological parameters that have known prognostic value, such as thickness and 
presence/absence of metastases (regional and distant). In addition, high serum levels of 
soluble MHC class I chain-related genes A (sMICA), an NKG2D ligand (NKG2DL) that may 
be involved in the mechanism of NK cell exhaustion, identify patients with shorter disease-
free and overall survival.  
We also identified Tim-3 as an inhibitory receptor over-expressed in NK cells from advanced 
melanoma patients that plays a key role in the exhausted phenotype of these cells. 
Significantly, we demonstrated that Tim-3 blockade partially reversed this exhausted 
phenotype. Therefore, in average, it was possible to enhance cytotoxicity by 20%, IFNγ 
production by 15% and proliferation by 60%. 
Finally, we characterized the effect of ipilimumab (anti-CTLA-4) on exhausted NK cells from 
advanced melanoma patients. Remarkably, NK cells from responders to ipilimumab treatment 
have higher levels of IL-2 receptor (IL-2R), and consequently, are more responsive to IL-2 
stimulation and more cytotoxic. 
	  





These data open exciting avenues for new NK cell-based therapies, including targeting Tim-3 
in the context of melanoma. Moreover, a better understanding of the mechanism behind NK 
cell exhaustion will help defining new prognostic markers and therapeutic strategies. 
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O melanoma é o quinto tumor maligno mais comum nos homens (sétimo nas mulheres) e a 
sua incidência está a aumentar mais rapidamente do que a de qualquer outro cancro. É o tipo 
de cancro cutâneo mais agressivo; corresponde a apenas 2% de todos os cancros de pele, mas 
é responsável por mais de 70% das mortes causadas pelo cancro cutâneo. O melanoma 
responde mal à terapia sistémica e tem mau prognóstico nos doentes com metástases à 
distância, com uma taxa de sobrevivência global aos 2 anos que varia entre os 18 e os 40%. 
No contexto do cancro identificamos duas respostas imunológicas opostas: uma resposta 
aguda anti-tumoral com predomínio de células Th1 podendo, consequentemente, levar a uma 
reacção auto-imune; e uma resposta inflamatória pró-tumoral, caracterizada por uma 
tolerância imunológica através de mecanismos imunossupressores. Durante a progressão do 
tumor verifica-se um desequilíbrio com um predomínio da resposta inflamatória pró-tumoral 
e disfunção das células anti-tumorais Th1. O conceito de "exaustão dos linfócitos T” tem sido 
desenvolvido nos últimos anos e pode explicar a disfunção das células Th1. Este conceito de 
"exaustão dos linfócitos T", consequência do microambiente tumoral ou de outros factores, 
foi descrita pela primeira vez em doenças infecciosas crónicas e mais recentemente em 
diferentes tipos de cancro, em particular no melanoma. Este fenótipo é caracterizado pela  
perda progressiva da capacidade de proliferação, do potencial citotóxico e da capacidade de 
produzir interleucina 2 (IL-2). A “exaustão dos linfócitos T” no contexto do cancro 
metastático tem sido reforçado pelo recente sucesso de imunoterapias dirigidas aos 
marcadores de exaustão expressados pelos linfócitos T, incluindo o CTLA-4 e o PD-1, em 
doentes com melanoma avançado. No entanto, o fenótipo e a função das NK em diferentes 
fases da progressão do tumor e a sua relação com fatores de prognóstico ainda é 
desconhecida. 
As células NK pertencem ao sistema imune inato e têm um papel importante na resposta anti-
tumoral. A função destas células depende do equilíbrio entre os receptores de activação e de 
inibição, e da expressão dos respectivos ligandos no microambiente tumoral. O Tim-3, outro 
marcador de exaustão dos linfócitos T juntamente com o CTLA-4 e o PD-1, comporta-se 
como um receptor inibitório nos linfócitos T e tem um papel fundamental para a manutenção 
da tolerância imunológica. O Tim-3 também é expresso nas células NK, no entanto o seu 
	  





papel na modulação da função destas células permanece pouco claro, em particular no 
contexto do cancro. 
Os objetivos deste estudo foram: caracterizar o fenótipo e a função das células NK em 
doentes com melanoma; identificar moléculas, que possam estar envolvidas no mecanismo da 
exaustão das células NK, como potenciais marcadores de prognóstico no melanoma; definir o 
papel do Tim-3 expresso nas células NK de doentes com melanoma avançado; e estudar o 
efeito do bloqueio de checkpoints imunológicos no fenótipo e função das células NK no 
contexto dos doentes com melanoma avançado. 
Os nossos dados mostraram que as células NK de doentes com melanoma avançado exibem 
um fenótipo de exaustão imunológica que é caracterizado por uma expressão aumentada dos 
receptores inibitórios KIR3DL1 e KIR2DL3, por uma expressão diminuida dos receptores de 
activação NKG2D, NKp46 e DNAM-1, por uma resposta deficiente à estimulação com IL-2, 
por uma regulação negativa dos fatores de transcrição T-bet e Eomes, e por um défice de 
função (citotoxicidade, produção de IFN-γ e proliferação). 
As células NK adquirem gradualmente este fenótipo de exaustão imunológica à medida que a 
doença avança dos estadios iniciais (estadios I e II) para estadios mais avançados (estadios III 
e IV). Curiosamente, este fenótipo de exaustão das células NK está associado as parâmetros 
clinico-patológicos com valor prognóstico conhecido, como a espessura e a presença/ausência 
de metástases (regionais e à distância). Além disso, níveis elevados de MICA solúvel (ligando 
do receptor NKG2D) no plasma podem estar envolvidos no mecanismo de exaustão das 
células NK e identificam doentes com sobrevivência global e tempo de livre de doença mais 
curtos.  
Neste trabalho também identificamos o Tim-3 como um receptor inibitório e com uma 
expressão aumentada nas células NK de doentes com melanoma avançado, e que desempenha 
um papel chave no fenótipo de exaustão destas células. Mais importante, mostramos ainda 
que o bloqueio do receptor Tim-3 consegue reveter, em parte, este fenótipo de exaustão, com 
um aumento da citotoxicidade em 20%, da produção de IFN-γ em 15% e da proliferação em 
60%. 
Finalmente, caracterizamos o efeito do ipilimumab (anti-CTLA-4) no fenótipo de exaustão 
das células NK de doentes com melanoma avançado. Notavelmente, as células NK de doentes 
	  





respondedores ao tratamento com ipilimumab apresentaram níveis mais elevados de IL-2R e, 
por conseguinte, maior citotoxicidade em resposta à estimulação com IL-2. 
Estes dados abrem caminho para novas estratégias terapêuticas com base nas células NK, 
incluindo o bloqueio do receptor Tim-3 no contexto de melanoma. Além disso, uma melhor 
compreensão do mecanismo subjacente à exaustão das células NK irá definir novos 
marcadores de prognóstico e estratégias terapêuticas. 
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CHAPTER 1:                                                          
INTRODUCTION & STUDY AIMS 
 
1.1. Introduction 
Melanoma is the deadliest skin cancer and its incidence is increasing dramatically. The 
median age at diagnosis is 59 years, and on average, an individual loses 20.4 years of 
potential life as a result of melanoma mortality, that is four years more than the average for all 
other malignancies1.  
Immune responses to cancer have been shown to play a role in control of tumor development 
(immunosurveillance). However, tumors continue to grow despite this immune pressure 
(immunoevasion). Two key processes are responsible for this immunoevasion phenomenon: 
(1) immunoediting, which refers to the role of the immune response in selecting tumor 
variants that have become poorly immunogenic (such as, loss or downregulation of human 
leucocyte antigen (HLA) class I molecules); and (2) immunosubversion, in which tumor cells 
or the tumor microenvironment (TME) suppress the immune response2. In fact, the cells 
responsible for anti-tumor immune responses, mainly T cells, NK cells and natural-killer T 
cells (NKT cells), seem to be dysfunctional in different advanced stages of tumors, partly as a 
result of the influence of the tumor2. 
The resistance of melanoma to standard treatments and the relevance of the immune response 
against melanoma, due to its high immunogenicity3,4, have led to the evaluation of different 
immunotherapies such as cytokine therapies, targeted antibody therapies, cellular 
therapeutics, as well as vaccines. A recent advance is the approval of anti-CTLA-4 and anti-
PD-1 antibodies, which have shown efficacy in the treatment of a substantial percentage of 
patients with advanced melanoma5, both individually and in combination6. However, the 
successful treatment of patients with advanced melanoma will require additional novel 
interventions. Therefore, identification of key molecules that modulate antitumor immunity 
and that could be used as a therapeutic target, as well as predictive markers of response to 
immunotherapy are essential.  
 
	  






Melanoma is the sixth most common cancer in men and women, and is the second most 
common cancer in women aged 20 to 29 in the United States. The incidence of melanoma has 
increased more than 690% since 1950, and it is estimated that 1 in 34 men and 1 in 53 women 
will be diagnosed with melanoma during their lifetime (from a recent epidemiological 
analysis between 2009-2011)7. Melanoma accounts for less than 2% of all skin cancer cases, 
but is responsible for the vast majority of skin cancer deaths8. A positive family history of 
melanoma, prior melanoma, multiple clinically atypical moles or dysplastic nevi and rarely 
inherited genetic mutations [cyclin-dependent kinase inhibitor 2D (CDKN2D) and cyclin-
dependent kinase 4 (CDK4)]9 are some of the risk factors for melanoma. Sun exposure also 
contributes to the development of melanoma, suggesting that the interaction between genetic 
susceptibility and environmental exposure contributes to the development of melanoma10. 
However, melanoma can occur in any ethnic group and in areas of the body without 
substantial sun exposure. 
 
1.1.1.1 Mechanisms of melanoma progression 
According to the Clark model of melanoma progression, the first change is the development 
of benign nevi, which results from benign controlled melanocyte proliferation. In this phase, 
proto-oncogene B-Raf (BRAF) mutations and the activation of the mitogen-activated protein 
kinases (MAPK) pathway may occur. The second step is the formation of a dysplastic nevus, 
which is considered a premalignant lesion and has some random atypia. These lesions have an 
aberrant growth and may reflect the loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) 
and phosphatase and tensin homolog (PTEN). The third step consists of the radial-growth 
phase, where melanoma cells acquire the ability to proliferate intraepidermally. This phase is 
associated with decreased differentiation and acquisition of melanoma markers regulated by 
microphthalmia-associated transcription factor (MITF). The fourth step represents the 
vertical-growth phase, where melanoma cells acquire the ability to invade the dermis and 
form an expansive nodule. Finally there is the metastatic phase, where melanoma cells 
successfully proliferate and establish metastases. These two last phases are notable for 
striking changes in the control of cell adhesion11. 
	  






1.1.1.2 Clinical-histopathological subtypes 
Melanoma has been classically categorized into four major clinical-histopathological 
subtypes: superficial spreading melanoma (SSM), nodular melanoma (NM), acral-lentiginous 
melanoma (ALM) and lentigo maligna melanoma (LMM)12. SSM is the most frequent 
histological type of melanoma (about 65% of all cases) and is characterized by the presence 
of a radial growth phase mostly composed of large epithelioid melanocytes distributed at all 
levels of the epidermis in a pagetoid fashion. It is associated with pre-existing nevi 
(congenital and dysplastic) in about 25% of the cases. It commonly occurs on the trunk in 
males and in lower extremities in females. NM is the second most frequent histological 
subtype of melanoma (it corresponds to 10 to 15% of all melanomas in caucasians). Unlike 
the other three main histological types, NM only has a vertical growth phase. The absence of 
a radial growth phase is the pathological landmark of this type of melanoma. ALM is a 
relatively rare type of melanoma (about 5% of all cases). It arises in the palms of the hands, in 
the soles of the feet and in the nailbed (subungual melanoma). ALM occurs rarely in 
caucasians, but encompasses 35% of the melanomas that develop in black people, hispanics 
or asians. The dismal prognosis of this variant of melanoma has been explained by its location 
at acral glabrous sites; a delayed diagnosis may contribute to worsen the prognosis. The radial 
growth phase of ALM is histologically characterized by a lentiginous proliferation of atypical 
melanocytes along the basal layer of the epidermis, and is associated with marked acantosis of 
the epidermis and elongation of the rete ridges. The vertical growth phase often presents a 
spindle cell component. Finally, LMM typically occurs in older people, on sun-exposed areas, 
mostly head and neck. LMM was considered to have a better prognosis than the other forms 
of melanoma, but recent studies have suggested that the different biologic behavior may be 
related to thinner tumors at the time of diagnosis. This variant of melanoma is histologically 
characterized by a confluent growth of atypical melanocytes along the dermal-epidermal 
junction. The invasive component may be composed of spindle cells or may be associated to a 
desmoplastic reaction13. 
More recently, melanomas have been divided according to a different classification based on 
the etiology. There are four main subtypes: chronic sun-induced damage (CSD), melanomas 
with chronic sun-induced damage characterized by the presence of marked solar elastosis; 
non-chronic sun-induced damage (non-CSD), melanomas without chronic sun-induced 
	  





damage; acral melanomas on the soles, palms, or sub-ungual sites; and mucosal melanomas 
on mucosal membranes. Interestingly, these subtypes display a different mutational profile. 
Therefore, while the non-CSD subtype melanomas has the highest proportion of BRAF 
mutations (56%) compared to CSD, acral, and mucosal subtypes (6%, 21%, and 3%, 
respectively), the incidence of KIT (proto-oncogene c-Kit or stem cell growth factor receptor) 
aberrations was 28%, 36%, and 39% in CSD, acral, and mucosal subtypes, respectively, but 
0% in non-CSD subtypes. NRAS (Neuroblastoma RAS oncogene) mutations were found in 
5% to 20% of the subtypes14. In the context of melanoma, the histologic subtypes have 
limited effect on the prognosis and treatment. However, recent studies have shown how 
histology driven molecular characterization can impact clinical decision-making in other solid 
tumor types15. For example, histopathological subtypes of lung cancer have been shown to be 
correlated with specific mutational profiles that determine the response to targeted therapies16. 
 
1.1.1.3 Staging 
Melanoma staging is determined by the American Joint Committee on Cancer (AJCC) 
system, that incorporates tumor thickness, ulceration, mitotic index, the lymph node status 
and distant metastases17. This staging system categorizes melanoma patients into three main 
groups: localized disease with no evidence of metastases (stage I–II), regional disease (stage 
III) and distant metastatic disease (stage IV) (Figure 1.1).  
In localized melanoma (stage I or II), tumor thickness, ulceration and mitotic rate are the three 
most important characteristics of the primary tumor-predicting outcome. Ulceration in 
melanoma corresponds to an interruption of the surface epithelium by tumor cells. Mitotic 
rate (MR) is a marker of tumor proliferation and is measured as the number of mitoses per 
mm2. MR greater than or equal to 1.0 per mm2 is independently associated with worse 
disease-specific survival (DSS), especially in patients with melanoma less than or equal to 1.0 
mm thick, and this is the criterion for upstaging patients with melanomas less than or equal to 
1.0 mm in thickness from IA to IB18,19. 
 
	  





             
 
In stage III melanoma, the most important predictors of survival are the number of metastatic 
nodes and clinical nodal status (nonpalpable vs. palpable). In the case of a positive sentinel 
lymph node, the number of positive nodes, tumor burden in the sentinel node, primary tumor 
thickness, mitotic rate, ulceration, and patient age are the most important prognostic factors. 
For patients with clinically positive nodes, prognostic factors include number of positive 
nodes, primary tumor ulceration, and patient age. 
The site of metastases is the most significant predictor of outcome among patients with distant 
metastases (stage IV). The three risk categories recognized by the AJCC are skin / soft tissue / 
remote nodes, visceral-pulmonary, and visceral-nonpulmonary. Elevated lactate 
dehydrogenase (LDH) is also an independent predictor of poor outcome in patients with stage 
IV disease and has been incorporated into the AJCC staging system17. 
There are other pathological factors that seem to influence the prognosis. Some of these 
factors include, tumor-infiltrating lymphocytes (TILs), angiovascular infiltration, microscopic 
satellites and regression. With respect to infiltration of TILs, melanomas are normally 
Figure 1.1. AJCC staging system for cutaneous melanoma. (Left) Tumor (T) Nodes (N) Metastases 
(M) staging. (Right) Clinical and pathological staging17. 
	  





classified as: brisk or diffuse response, defined as lymphocytes throughout the tumor; non-
brisk or focal, defined as only foci of infiltration rather than through the whole of the tumor; 
and absent TILs, defined by “no lymphocytes present”20. On a multivariate analysis of data 
from a prospective clinical trial, TILs response was a significant predictor of sentinel lymph 
node (SLN) metastasis, not a significant independent factor predicting disease-free survival 
(DFS) or overall survival (OS)21. However, the prognostic significance of TILs response in 
cutaneous melanoma is still controversial22. Microscopic satellites are defined as dermal or 
subcutaneous nests of metastatic cells more than 0.05 mm in diameter that are clearly 
separated from the main lesion by at least 0.3 mm, and the survival outcome is comparable to 
that of patients with clinically detectable satellite metastases. Regression corresponds to a 
partial host response to a malignant neoplasm, resulting in focal decrease of the process. 
Histologically, the changes are similar to those seen in a scar, with an infiltrate of 
lymphocytes admixed with histiocytes and pigment-laden macrophages underlying an 
atrophic epidermis with flattened rete ridges23. The prognostic value of regression is still 
controversial. While some results suggested that those melanomas with regression have a 
lower frequency of sentinel node involvement, others indicate that regression is associated 
with poor prognosis because the disappearance of a portion of the tumor may lead, at least in 
some cases, to an underestimation of the original Breslow thickness24. 
 
Patients with stage I melanoma have an excellent prognosis, with 5-year survival achieved in 
more than 90% of the patients. For patients with localized melanomas thicker than 1.0 mm 
(stage II), survival rates range from 50% to 90%. Within stage III, 5-year survival rates range 
from 20% to 70%, depending primarily on the nodal tumor burden (Figure 1.2). Long-term 
survival in patients with distant metastatic melanoma, taken as a whole, is less than 10%, 
however, this scenario is changing with new therapeutic strategies25,17.  
 
	  










The primary treatment for local melanoma (stage I, II and III) consists of surgical excision 
with safety margins: margins of 0.5 cm for in situ melanomas, of 1 cm for tumors with a 
Breslow thickness of up to 2 mm and 2 cm for thicker tumors26. SLN biopsy aims to identify 
patients with subclinical nodal metastases at higher risk of recurrence, who could be 
candidates for complete lymph node dissection or adjuvant systemic therapy. SLN biopsy is 
necessary for precise staging in melanomas with a tumor thickness of >1 mm and/or 
ulceration27. In the cases that the sentinel node was found positive for metastases, a complete 
lymphadenectomy of regional lymph nodes was the standard treatment. However, a recent 
study showed that, even though a complete lymphadenectomy leads to a better disease control 
in the regional lymph node basin, it is not associated with improved distant metastases-free 
survival, recurrence-free survival or melanoma-specific survival28. 
For patients with stage III melanoma, adjuvant treatment may be considered. These 
therapeutic options include, observation, clinical trials or interferon alfa (IFN-α). Even though 
melanoma is poorly radiosensitive, adjuvant radiotherapy (RT) may be considered for 
selected patients with clinically positive nodes and features predicting a high risk of nodal 
basin relapse29. Adjuvant high-dose and pegylated interferon are both appropriate options for 
patients with completely resected stage III disease, either positive sentinel nodes or clinically 
positive nodes30,31. Many different treatment options, mostly locoregional, are available to 
patients presenting with stage III in-transit metastases. Treatment is based on the size, 
Figure 1.2. Survival curves using the AJCC melanoma staging. (Left) Different stage 
groupings for stages I and II melanoma. (Right) Different stage groupings for stage III17. 
	  





location, and number of tumor deposits, but evidence is limited and there is no consensus on 
the optimal approach. Excision with clear margins is the mainstay for resectable regional 
recurrence. Although in-transit disease has a high probability of clinically occult regional 
nodal involvement, and a positive sentinel node in the presence of in-transit metastasis 
portends a more ominous prognosis, the impact of SLN biopsy on outcome remains unknown. 
A number of non-surgical local approaches are being used. These include intralesional local 
injections with bacillus Calmette-Guérin (BCG), IL-2 or IFN-α, laser ablation and topical 
imiquimod32. Isolated limb perfusion or infusion are techniques to regionally administer high 
doses of chemotherapy (melphalan is the drug most widely used for this technique) to an 
affected extremity while avoiding systemic drug exposure33. Moreover, ipilimumab 
(10mg/Kg) was also studied in the adjuvant setting in a double-blind phase 3 trial 
(NCT00636168), and showed an improved recurrence-free survival. Nevertheless, the distant 
metastasis-free survival and overall survival endpoints need to be clearly assessed in order to 
define the risk-benefit ratio of ipilimumab in this context34. 
Disseminated disease can be managed by systemic therapy, clinical trial, or best supportive 
care. Preferred regimens include ipilimumab (anti-CTLA-4)35, nivolumab or pembrolizumab 
(anti-PD-1), vemurafenib or dabrafenib (BRAF inhibitor), cobimetinib or trametinib 
(MAPK/Erk kinase (MEK) inhibitor), or even BRAF and MEK inhibitors combination 
therapy. Vemurafenib and dabrafenib are recommended only for patients with documented 
V600 BRAF mutations36,37. BRAF inhibitors can be used alone, or in combination with MEK 
inhibitor for patients who have progressed from previous treatment with BRAF inhibitors38. 
Phase III data pointed out that combination therapy is superior over targeted monotherapy in 
terms of toxicity and efficacy39,40. Trametinib monotherapy can be used in patients who show 
intolerance to toxicities related to vemurafenib or dabrafenib. The recommendation for first-
line systemic therapy of melanoma is based on several factors, including the BRAF mutation 
status, the kinetics of disease, and the presence/absence of cancer-related symptoms. 
Therefore, patients with low-volume, asymptomatic metastatic melanoma may be good 
candidates for immunotherapy (anti-CTLA-4 or anti-PD-1), independently of their BRAF 
status, as there may be time for a durable antitumor immune response to emerge. Patients with 
BRAF-mutant melanoma who have symptomatic disease or who have progressed despite 
immunotherapy should be considered for targeted therapies. Clinical trials are underway to 
address unanswered questions regarding the optimal sequencing and/or combination of these 
	  







1.1.2. Immunotherapy in melanoma      
Cancer immunotherapy includes different strategies that aim to stimulate the immune system 
to obtain a specific and lasting antitumor response, with consequent clinical benefit. This 
concept originated in 1891 with William Coley, a surgeon from New York, who observed the 
regression of sarcomas in patients who developed erysipelas, and tried to reproduce this effect 
by injecting live or inactivated Streptococcus pyogenes and Serratia marcescens in cancer 
patients. Since then various attempts to boost the immune system, mainly by vaccines and 
cytokines, were made in the context of clinical trials, but with disappointing results. In recent 
years, we witnessed an important inflection point in the history of cancer immunotherapy, 
wherein new strategies mainly immune checkpoints blockade, have shown long-term clinical 
responses in different tumors5,35.  
 
1.1.2.1 Regulation of antitumor immune response 
Understanding the development and regulation of the anti-tumoral immune response is 
essential for devising strategies that can improve anti-tumor immunity. An immune response 
occurs in multiple stages and simply can be divided into three phases: (1) maturation of 
dendritic cells (DC) for effective antigen presentation; (2) priming and activation of anti-
tumor T cells; (3) an adaptive immune response to overcome the immunosuppressive 













In the first step there is capture of tumor antigens by DCs. These antigens include proteins 
derived from mutated or non-mutated genes, preferentially expressed by tumor cells. In order 
to process the antigens properly and effectively, DCs must receive a "maturation" sign, for 
example, by stimulation of toll-like receptors (TLR) and CD40 (costimulatory molecule). 
These cells migrate to the draining lymph nodes and present the processed antigens as 
peptides to T lymphocytes via major histocompatibility complexes (MHC) class I and II. For 
the generation of effective T cells against the tumor to occur, an interaction between 
costimulatory molecules present on T cells (CD28, OX40 (CD134)) and on DCs 
(CD80/CD86 and OX40L (CD252)) is needed. Finally, activated T cells are mobilized and 
infiltrate the tumor, in order to destroy it. However, many tumor cells develop mechanisms of 
escaping this immune response, such as increased programmed (cell) death-ligand 1 (PD-L1) 
expression and secretion of vascular endothelial growth factor (VEGF) by tumor cells, and 
secretion of IDO (indoleamine 2,3-dioxygenase) by T regulatory cells (Tregs), creating an 
immunossupressive TME2. 
In the context of melanoma, different strategies of immunotherapy have been developed to 
operate in each of these different phases in order to control tumor progression. They are 
divided into four main groups: (1) vaccines42; (2) cytokines (IL-2 and IFN-α)43; (3) adoptive 
Figure 1.3. Anti-tumor immune response and different immunotherapy strategies2. 
	  









The goal of vaccination is to generate an anti-tumor response, based on CD4+ and CD8+ T 
lymphocytes against tumor-specific antigens, that is sufficiently robust to be able to produce 
long-lasting clinical responses42. Here we review these approaches, and highlight some of the 
failures and promising new vaccines.  
The vaccine containing the melanoma associated antigen 3 (MAGE-A3) peptide was studied 
in a phase I/II clinical trial with 32 MAGE-A3+ melanoma patients. Only 26 patients received 
at least four vaccinations, and one partial response and four mixed responses were observed47. 
In a phase II study, the combination of AS15 adjuvant (containing CpG 7909, 
monophosphoryl lipid and QS-21) plus MAGE-A3 peptide enhanced the immune response 
and was associated with tumor regression48. This provided the rationale for the development 
of a phase III trial with this vaccine in the context of melanoma and lung cancer. 
Unfortunately this trial failed to meet its endpoints and was halted.  
Another vaccine based on irradiated melanoma cells, called CanvaxinTM, was studied in a 
non-randomized trial and showed promising results compared to the historical control (overall 
survival at 5 years of 39% patients with the vaccine compared to 19% without the vaccine)49. 
However, this advantage was not confirmed in a phase III trial where this vaccine was used in 
the adjuvant setting in 1656 patients with resectable stage III/IV melanoma. In order to 
improve the quality of adjuvants, vaccines have been developed consisting of melanoma cells 
that secrete granulocyte-macrophage colony-stimulating fator (GM-CSF), often referred to as 
G-VAX. While the GM-CSF gene vaccine (GVAX) alone has not secured a high level of 
resposnes, it is still being considered in combination with other interventions e.g. an ongoing 
phase I trial with allogeneic melanoma cell GVAX with or without cyclophosphamide in 
resected high-risk melanoma50. 
The T-VEC vaccine (talimogenelaherparepvec), consisting of attenuated herpes simplex virus 
(HSV) associated with GM-CSF, was studied in a phase III trial (2:1) with 436 unresectable 
stage IIIA/B/C melanoma patients. The vaccine or the GM-CSF alone were injected into the 
	  





tumor, with an overall objective response of 26.4% and 5.7% for the arms of the T-VEC 
vaccine and GM-CSF, respectively51. This vaccine is now being studied in combination with 
immune checkpoints (ipilimumab) in advanced melanoma patients52, and also in the 
neoadjuvant setting53.  
 
1.1.2.3 Cytokines 
Cytokines are a diverse group of proteins important for immune system regulation. Two 
cytokines, IL-2 and IFN-α, have been approved by the Food and Drug Administration (FDA) 
for patients with stage IV and unresectable stage III melanoma, respectively. 
IL-2 stimulates the proliferation and activity of T and NK cells and is associated with 
regression of some immunogenic tumors, such as kidney cancer and melanoma. High dose 
recombinant IL-2 was approved by the FDA in 1998 for patients with stage IV melanoma 
with good performance status54. Up to 5% of patients can exhibit a response to IL-2 but its use 
is less ferequent due to its toxicity and the advent of other treatments. 
Pegylated interferon-α2b (PEG-IFNα-2b) is IFNα-2b conjugated with a polyethylene glycol 
molecule which confers a longer half-life. This compound was approved by the FDA in 
March 2011 for the adjuvant treatment of patients with stage III melanoma based on a 
randomized, multicenter, phase III clinical trial. This study was positive, with significant 
improvement in the primary endpoint, disease-free interval [hazard ratio (HR)=0.86; 
p=0.036)]; however, the difference in survival rate between the groups of patients treated with 
PEG-IFNα-2b and patients who remained under observation was not statistically different 
(HR = 0.98; p = 0.78)30. Thus, the approval of PEG-IFNα-2b for patients with stage III 
melanoma was based on a longer and clinically significant disease-free interval. 
Subsequently, a meta-analysis that included 14 trials with interferon showed a slight, but 
statistically significant, advantage in disease-free interval in patients with high risk cutaneous 
melanoma31. 
Currently, with new therapeutic options, cytokines are not as used in the treatment of 
melanoma as a single agent, but they remain a valid option in combination with other drugs. 
 
	  





1.1.2.4 Adoptive transfer of cells 
This therapy consists of the extraction of TILs, their expansion and activation ex vivo, 
followed by infusion of these cells into the patient. In a National Cancer Institute (NCI) 
clinical trial, patients were previously submitted to Total Body Irradiation (TBI - 2 Gy or 
12Gy) and to a non-myeloablative regimen with fludarabine and cyclophosphamide, while the 
cells were expanded with the T-cell stimulating anti-CD3 monoclonal antibody (OKT3) and 
IL-2. In this study, objective responses according to Response Evaluation Criteria in Solid 
Tumors (RECIST), were observed in 49% to 72% depending on the conditioning regimen 
prior to the cells’ infusion. This study showed that the persistence of clones of T cell infused, 
as well as the length of the telomeres were associated with better clinical responses44,55,56. 
 
1.1.2.5 Immune checkpoints 
Immune checkpoints are a family of inhibitory receptors that play a fundamental role in the 
maintenance of immunological tolerance, by modulating the duration and amplitude of the 
physiological immune response, in order to prevent autoimmunity. Consequently, they can 
prevent a robust and effective antitumor response, contributing for tumor progression. This 
family of immune checkpoints includes different molecules, such as CTLA-4, PD-1, Tim-3, 
lymphocyte activation gene 3 (LAG-3), B- and T-lymphocyte attenuator (BTLA), amongst 
others45,46. 
 
CTLA-4 is exclusively expressed by T cells, varying according to the activation state and 
subtype of these cells. This receptor is mostly intracellular, but following activation it is 
rapidly expressed in the membrane. Both CTLA-4 and CD28 (an activating receptor), bind to 
CD80 and CD86 receptors on DCs, however the affinity of CTLA-4 to CD80/CD86 is 
approximatly 40 times higher compared with the affinity of CD28 to the same receptors. For 
this reason even a low level expression of CTLA-4 in the membrane of T cells can block the 
CD28-CD80/CD86 interaction, preventing the activation of these cells45. The effect of CTLA-
4 can be observed in two different contexts: inhibition of CD8+ and CD4+ Th and activation 
of Treg (regulatory T cells). CTLA-4 regulates immune responses in an early and critical 
phase of T cell activation, as evidenced by the phenotype developed by CTLA-4-/- mice, 
	  





which are characterized by a fatal lymphoproliferative disorder in 3-4 days57. In preclinical 
studies it was shown that blockade of this receptor by monoclonal antibodies led to an 
improvement of the activity of CD4+ T cells, increased CD8+ T cells:Tregs ratio and 
inhibition of Tregs in tumor models with some endogenous immune response, or even in 
poorly immunogenic tumors when combined with a vaccine.  
These pre-clinical findings led to the development of two anti-CTLA-4 monoclonal 
antibodies: tremelimumab and ipilimumab. In a phase III trial the effect of tremelimumab 
(n=328; 15mg/kg 3/3 months) was compared with that of chemotherapy (n=327; dacarbazine 
1000 mg/m2, or temozolomide 200 mg/m2) in patients with advanced melanoma. Although 
several patients had long-lasting responses, there was no improvement in survival 
(p=0.127)58, probably due to the dosing schedule and patient selection59.  
The first phase III trial with ipilimumab for previously treated patients with unresectable stage 
III/IV melanoma was published in 2010 in the New England Journal of Medicine (NEJM). 
This study compared three arms: ipilimumab (n = 137; 3mg/kg 3/3 weeks, 4 cycles), gp100 
vaccine (n = 136) and the combination ipilimumab + gp100 vaccine (n = 403). There was a 
distinct advantage of the arms that contained ipilimumab compared with the vaccine, with a 
survival rate at 2 years of 14%, 22% and 24% in the vaccine, combination and ipilimumab 
groups, respectively. The median survival on the ipilimumab arm was 10.1 months compared 
with 6.4 months in the arm of the gp100 vaccine (HR=0.68; p<0.001)35 (Figure 1.4). Based 
on these results the FDA approved this drug for the treatment of metastatic melanoma in 
March 2011. Another Phase III trial included 502 patients with untreated advanced melanoma 
that were randomized to treatment with dacarbazine (850mg/m2) plus placebo or dacarbazine 
(850mg/m2) plus ipilimumab (10mg/kg). The primary objective of this study was OS and this 
was higher in the dacarbazine + ipilimumab arm (HR=0.72; p<0.001). There was also a 
higher percentage of adverse effects in this group, mainly gastrointestinal disorders (p 
<0.001)60. 
	  









More recently, PD-1 emerged as a new therapeutic target with improved response rates and a 
better toxicity profile. PD-1 limits the activity of T cells at different stages of the immune 
response through interaction with their natural ligands, PD-L1 and programmed (cell) death-
ligand 2 (PD-L2). This inhibition occurs in the peripheral tissues and in the TME, by 
inhibiting signaling pathway dependent kinases that activate T cells through the activity of a 
non-receptor tyrosine kinases (Src) homology region 2 domain-containing phosphatase-1 and 
-2 (SHP-1 and SHP-2). Contrary to CTLA-4, PD-1 is expressed in other immune cells other 
than T cells, including B and NK cells. Therefore PD-1 blockade will have an effect on the 
function of these different cells45. 
Several anti-PD-1 monoclonal antibodies have been developed, of which pembrolizumab and 
nivolumab have been approved by the FDA in September and December 2014, respectively. 
A phase II study published in NEJM 2012, assessed the safety and antitumor activity of 
nivolumab with a dose ranging from 0.1-10.0mg/kg 2/2 weeks. This study enrolled 236 
patients (76 lung cancer, 94 melanoma, 33 kidney cancer) and had a 18% response rate for 
lung cancer, 28% for melanoma and 27% for kidney cancer61. Survival analysis in this study 
showed a median survival of 16.8 months, with survival rates at 1 and 2 years of 62% and 
Figure 1.4. Overall survival for advanced melanoma patients treated 
with: vaccine gp100; ipilimumab; vaccine gp100 + ipilimumab35. 
	  





43%, respectively62. Two other studies compared nivolumab with chemotherapy in different 
contexts. In one of the trials, treatment with nivolumab (n=268; 3mg/kg) was compared with 
chemotherapy (n=102; dacarbazine 1000 mg/m2; or carboplatin AUC 6 + Paclitaxel - 175 
mg/m2). There was an advantage in the nivolumab arm with a response rate of 32% compared 
with 11% in the chemotherapy arm in melanoma patients who progressed under ipilimumab63. 
In the other study, nivolumab (3 mg/kg) was compared with dacarbazine (1000 mg/m2), in 
418 patients with melanoma BRAFWT without previous treatment. This study showed an 
improvement in survival at one year in the nivolumab group (72.9%) compared with 42.1% in 
the dacarbazine group (HR=42, p<0.001)64. In the trial with the pembrolizumab (formerly 
lambrolizumab), 135 patients with advanced melanoma (with or without pretreatment with 
ipilimumab) were included and different doses were tested: 10 mg/kg every 2/3 weeks or 2 
mg/kg every 3 weeks. There was a 38% response rate according to RECIST with the highest 
response rate in the cohort who received the highest dose (10 mg/kg). There was no 
significant difference between patients previously treated or untreated with ipilimumab65. 
 
PD-L1 is one of the natural ligands of PD-1 and CD80, which is expressed by the tumor cells, 
stromal cells and immune cells in the TME. It limits PD-1 activity on tumor-infiltrating CD4+ 
or CD8+ cells. For this reason PD-L1 has become an interesting therapeutic target; the anti-
PD-L1 monoclonal antibodies inhibit not only the binding of the receptor to PD-1, but also to 
CD80. In a phase I trial 207 patients with solid tumors (55 advanced melanoma patients) were 
recruited and treated with anti-PD-L1 (doses ranging from 0.3 to 10mg/kg). This antibody 
showed response rates between 6-17% and stabilization of the disease in 12-41% of cases of 
melanoma, lung and kidney, and a safe profile, with grade 3/4 adverse events experienced by 
9% of the patients66. 
 
1.1.2.6 Immunotherapy Dynamics 
The pattern of the clinical response to immunotherapy is completely different from that seen 
with chemotherapy. Through immunotherapy the immune system is modulated in order to 
effectively fight the tumor, which can lead to different responses that may affect therapeutic 
decisions. Firstly, sometimes, before a clinical and radiological response takes place, there 
may be an increase in tumor size or even the appearance of new lesions. Therefore, new 
	  





response evaluation criteria for evaluating immunotherapy - the immune-related response 
criteria (IRRC) - were proposed. Secondly, the responses to immunotherapy are often late 
responses and may happen after several weeks or months of treatment. Finally, these 
responses tend to be long-lasting67. Recently a pooled analysis that included 1861 patients 
treated with ipilimumab, from different studies (10 prospective and retrospective 2, including 
two clinical phase III trials), showed a survival rate at 3 years of 22%, which remained in a 





1.1.2.7 Immunological adverse effects 
There is a clear long-term advantage in using the above-mentioned recent immunotherapy 
strategies, however they also present a downside. These treatments are associated with 
different side effects as a result of a nonspecific and exaggerated immune response, resulting 
in an autoimmune reaction. The percentage of grade 3-4 adverse events related to 
immunotherapy is similar to that observed with chemotherapy (approximately 10% to 20%), 
however they show different patterns. The most common toxicities that result from 
immunotherapy include itching with or without skin rash, diarrhea, colitis, hepatitis and 
endocrinopathies35,61,69. Dermatological toxicity is the most common and has an early onset 
(few weeks). It is characterized by an erythematous, pruritic, maculopapular rash on the trunk 
Figure 1.5. Overall survival of patients treated with 
ipilimumab from 12 different studies (pooled analysis)68. 
	  





and limbs and is generally treated with topical corticosteroids and antihistamines. Patients 
with severe rashes, such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have 
to be admitted and treated with intravenous corticosteroids and hydration. The second most 
frequent side effect is diarrhea that is often associated with colitis, which usually appears after 
the 6th week. Mild cases of diarrhea are controlled with oral steroids, while more severe cases 
may need hospitalization and treatment with intravenous corticosteroids and infliximab. The 
elevation of transaminases (AST and ALT) is more frequent during treatment with anti-
CTLA-4 treatment than with anti-PD-1, and is often asymptomatic. When these cases of 
hepatitis are symptomatic they should be treated with oral or intravenous steroids according to 
their severity, and mycophenolate mofetil should be added when necessary. The 
endocrinopathies may reach different glands including thyroid, adrenal and pituitary. 
Hormone monitoring and replacement must be done according to the clinical picture69. 
 
1.1.2.8 Response markers to immunotherapy 
We are approving powerful therapeutic weapons that are extremely expensive from an 
economic point of view and that are also associated with important adverse effects. For this 
reason, these new strategies should be offered only to patients who will respond to the 
treatment; therefore biomarkers predictive of response need to defined. Regarding treatment 
using ipilimumab, absolute lymphocyte count has been described as a pharmacodynamic 
biomarker and an increase of this cell count is associated with improved survival70. In the case 
of anti-PD-1, PD-L1 seems to play this role. In a phase I clinical trial Topalian et al showed, 
in a small cohort (n=42), that the lack of PD-L1 expression by the tumor cells is associated 
with no clinical response to nivolumab (anti-PD-1)61,62. Later Weber et al. studied a larger 
cohort (n = 90) and set a new cut-off, showing that 67% of patients with 5% PD-L1+ tumor 
cells responded to the nivolumab while only 19% of PD-L1- patients responded to the same 
treatment71. Moreover, in a recent phase I trial, pembrolizumab (anti-PD-1) was shown to be 
more effective in Non–Small-Cell Lung Cancer (NSCLC) with more than 50% PD-L1+ tumor 
cells72. The controversy remains and the best method of quantification of PD-L1 expression in 
the tumor, as well as the best cut-off and the true relationship with response to therapy, still 
need to be determined. Recent studies have shown that tumor mutational load and, more 
	  





importantly, a signature of somatic neoantigens are associated with clinical response to 
treatment with immune checkpoint inhibitors73,74. 
 
1.1.2.9 Strategies based on the combination 
Immune checkpoint inhibitors have been effective against more immunogenic tumors, such as 
melanoma, kidney and lung cancer. Thus, several strategies have been designed to render 
tumors more immunogenic, such as low-dose chemotherapy, radiotherapy or even vaccines. 
The combination of these monoclonal antibodies with conventional chemotherapy was shown 
to be associated with liver toxicity without significant clinical response. The same was 
observed with the combination of ipilimumab (immune checkpoint inhibitor) with 
vemurafenib (BRAF inhibitor); moreover, the liver toxicity was so severe that the treatment 
had to be stopped75. On the other hand, a few retrospective studies have showed an advantage 
in clinical response and survival in patients who received radiotherapy in combination with 
ipilimumab76. These studies constitute the rationale for conducting clinical trials with this 
combination which are currently in enrollment phase77. The results of a phase II study that 
enrolled 245 patients with stage III/IV unresectable melanoma (naïve of treatment) treated 
with ipilimumab (10mg/kg) +/- GM-CSF were presented at American Society of Clinical 
Oncology (ASCO) meeting in 2013. Although no significant difference was observed in the 
response rate between the two groups, the group treated with the combination therapy showed 
greater overall survival rate (17.5 months) compared with the isolated ipilimumab group (12.7 
months)78. 
Although CTLA-4 and PD-1 belong to the same family of immune checkpoints, they have 
different roles. While the interaction between CTLA-4 and its ligand B7 occurs in the lymph 
node, the PD-1 binding to PD-L1 occurs specifically in the TME. We are faced with two 
different but complementary mechanisms of T lymphocyte inhibition by the CTLA-4 and PD-
1; therefore, there is a biological rationale behind the combination of anti-CTLA-4 with anti-
PD-1. From a clinical point of view, this combination was associated with great results, with 
53% objective response (all with 80% tumor reduction) in the cohort with the highest dose 
combination (nivolumab 1mg/kg; ipilimumab 3mg/Kg)79. The first results of OS of this study 
were presented at the ASCO meeting in 2014, with 2 years survival greater than 80% in some 
schemes80, however these clinical responses were associated with significant toxicity. Grade 
	  





3-4 side effects were observed in more than 50% of patients and were qualitatively similar to 
previous studies with monotherapy and generally reversible. More recently, the results of the 
phase III study of the combination ipilimumab plus nivolumab were presented at the ASCO 
meeting in 2015 and published in the NEJM. Among previously untreated patients with 
metastatic melanoma, nivolumab alone (3mg/kg q2w) or combined with ipilimumab (Nivo 
1mg/Kg q2w + IPI 3mg/Kg q3w) resulted in significantly longer progression-free survival 
than with ipilimumab alone (IPI 3mg/Kg q3w). Remarkably, in patients with PD-L1– tumors, 
the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone, 
while in patients with PD-L1+ tumors nivolumab alone seemed to be as effective as the 






Immunotherapy is gaining increasing attention as a treatment of different types of cancer, as it 
is associated with long-lasting clinical responses. However, much still needs to be done, not 
only to be able to identify the long term responders, but also to increase the proportion of this 
group of patients and to identify markers of resistance. The answer may lie in the combination 
Figure 1.6. Progression-free survival of patients treated with ipilimumab, nivolumab or 
the combination ipilimumab+nivolumab in PD-L1-positive tumors (Upper plot) and in 
PD-L1-negative tumors (Lower plot)81. 
	  





of different immunotherapy strategies as well as in the association of immunotherapy with 
other types of treatment. 
 
1.1.3. Immune exhaustion  
Various states of T cell dysfunction have been described as a consequence of altered 
activation and differentiation processes including exhaustion, tolerance, anergy, senescence, 
and even ignorance. Tolerance in self-antigen specific T cells is a dysfunctional state required 
to prevent autoimmunity (self-tolerance), as a consequence of both central and peripheral 
immune tolerance mechanisms. In central immune tolerance, the thymocytes expressing T 
cell receptors (TCR) of too high affinity for self-antigen/MHC complexes are eliminated. 
Peripheral immune tolerance consists of deletion or suppression of self-reactive T cells that 
escape negative selection. Self-ignorance, in contrast to self-tolerance, is a state of no cell 
dysfunction, and is a consequence of antigen-inexperience. Therefore, “self-ignorant” T-cells 
persist as naïve, although they are potentially functional in the periphery. Anergy is 
commonly described as the dysfunctional state of T cells stimulated in the absence of co-
stimulatory signals. Senescence is another cellular process that induces T cell impairment as a 
consequence of low-grade antigenic stimulation. Numerous mechanisms have been proposed 
to cause cellular senescence, such as repeated cell division, telomere shortening, and damage 
by reactive oxygen species (ROS)82. Senescent T cells lose the co-stimulatory molecule CD28 
and their proliferative capacity, maintaining their cytotoxic activity and secretion of tumor 
necrosis factor alpha (TNF-α) and IFN-γ83. Finally, T cell exhaustion results from a chronic 
high-grade antigenic stimulation and refers to a state wherein T cells fail to respond to 
cytokines, proliferate or exert their effector cell functions (further details will be developed in 
the next section). 
 
1.1.3.1 Immune cell exhaustion 
Exhausted T-cell responses have been documented following numerous infections, including 
infections with human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis 
C virus (HCV), and have also been observed in patients with malignancies84,85, as a 
consequence of chronic antigenic stimulation. Therefore, the levels and duration of antigenic 
	  





stimulation are critical determinants of this process and decreasing antigen availability, as 
occurs during treatment, generally helps the exhausted T-cell population regain their 
functional phenotype86,87. CD4+ T cells have multiple effects on the overall immune response 
following infection and are often required for optimal CD8+ T-cell responses. As a 
consequence, any abnormalities in, or loss of, CD4+ T cells during the course of an infection, 
which can occur as these cells succumb to exhaustion, render CD8+ T cells less effective. 
Moreover, severe chronic infections and tumors are associated with a higher expression of 
immunosuppressive cytokines, such as IL-10 and transforming growth factor-beta (TGF-β). 
IL-10 has multiple effects and it has been shown to reduce pro-inflammatory cytokine 
production, impede the functions of antigen-presenting cells (APCs), dampen T-cell responses 
and also affect B cells88. This cytokine is produced by CD4+ T cells, including regulatory T 
cells, as well as by many other cell types such as DCs, macrophages, B cells and CD8+ T 
cells. The relationship between IL-10 and T-cell exhaustion has been well studied using the 
lymphocytic choriomeningitis virus (LCMV) system, since chronic LCMV infection is 
associated with T-cell exhaustion and elevated levels of IL-10. Moreover, the administration 
of antibodies that block the IL-10 receptor immediately following infection, as well as a 
therapeutic regimen given after the infection had taken hold, resulted in lower viral loads, 
decreased expression of PD-1, and improved the functionality of the virus-specific T cells89. 
The immunosuppressive cytokine TGF-β has been implicated in regulating the size of the 
pathogen-specific T-cell responses and the propensity of these cells to undergo apoptosis. The 
significance of the TGF-β pathway on the development of exhaustion has been further 
dissected following LCMV clone 13 infection. Interestingly, elevated levels of TGF-β were 
observed under these conditions and the TGF-β pathway appears to regulate the extent of the 
response but not directly influence the functional capacity of the cells. 
T-cell exhaustion is a progressive and stepwise process, where IL-2 production and 
proliferative ability are the first effector activities to be extinguished, followed by TNF-α 
production and cytotoxic activity (decreased production of perforin and granzymes), whereas 
the ability to produce IFN-γ is more resistant to inactivation90. In addition, as T cells acquire 
this exhausted phenotype, they start expressing inhibitory receptors, including Tim-3, PD-1 
and LAG-3, while losing some activating receptors, such as CD43 (sialoglicoproteina), CD44 
(cell adhesion molecule) and CD69. Furthermore, changes in the profile of transcription 
factors is also observed, with lower levels of T-bet and Eomes, and higher levels of B 
	  





lymphocyte-induced maturation protein-1 (BLIMP-1)91. The grade of functional impairment 
is a consequence of antigen load, duration of the infection and of CD4+ T cell help and 
translates into distinct patterns of co-expression of inhibitory receptors (Figure 1.7). T cells 
also display an “exhausted phenotype” in the context of advanced cancers due to high tumor-
antigen load and immunosuppressive factors in the TME. Therefore, T cells isolated from 
human tumors as well as experimental tumor models share many phenotypic and functional 





Figure 1.7. Sequential phenotypic and functional changes during the T-cell 
exhaustion process. Granzyme B (GranB); L-selectin (CD62L, cell adhesion 
molecule)91. 
	  





Defects in NK cell activity have been described in patients with various metastatic 
malignancies, including melanoma94,95,96,97. Some hypotheses have been postulated to explain 
this dysfunctional phenotype including upregulation of MHC molecules, high expression of 
immunosuppressive cytokines (IL-10 and TGF-β), contact with myeloid-derived suppressor 
cell (MDSC), tumor-associated macrophages (TAM) or Tregs, or even chronic stimulation 
with soluble NKG2D ligands (MHC class I chain-related genes A and B - MICA and MICB)3. 
Nevertheless, there is little characterization of an “exhausted NK cell state” in metastatic 
disease, nor of the mechanisms that might underlie this phenotype.  
Different strategies, including adoptive transfer of NK cells, have been attempted to control 
tumor growth, however they have been associated with mixed benefit. These disappointing 
results could be due to development of NK cell exhaustion. Indeed, adoptively transferred 
murine NK cells that trafficked to tumor sites, became rapidly dysfunctional and failed to 
control tumor growth98. NK cell “exhaustion,” therefore, could explain the failure of NK cells 
to contain tumor growth in advanced cancers.  
 
1.1.3.2 Exhaustion markers 
Functional exhaustion is accompanied by a marked change in T cell phenotype, characterized 
by constitutive expression of inhibitory receptors (PD-1 and CTLA-4), which act 
synergistically to negatively regulate the functional and proliferative potential of the 
responding cells.  
PD-1 is a type I transmembrane glycoprotein and is a member of immunoglobulin 
superfamily that contains a single V-set domain in its extracellular domain. The cytoplasmic 
domain contains one immunoreceptor tyrosine-based inhibitory motif (ITIM) domain and one 
immunoreceptor tyrosine-based switch motif (ITSM) domain, each of them containing a 
tyrosine residue. This receptor is expressed during thymic development primarily on CD4-
CD8- T cells, and is induced not only on peripheral T cells but also on B cells, monocytes and 
NK cells upon activation99. The main role of PD-1 is to control the T cell response in 
peripheral tissues at the time of an inflammatory response. This results in a decrease of 
autoimmunity but also in an inefficacious anti-tumor response. PD-L1 and PD-L2 are 
upregulated in response to inflammation and have different patterns of expression, while PD-
	  





L1 is expressed on many cell types, including hematopoietic, endothelial and epitelial cells, 
PD-L2 is upregulated on DCs and macrophages. When PD-1 binds to its ligands, ITSM 
becomes phosphorylated and recruits SHP-2 that inhibits kinases involved in T cell 
activation100. PD-1 crosslinking inhibits the TCR signal, decreasing the duration of T cell-
APCs or T cell-target cell contact. Therefore, PD-1 plays a role in establishing peripheral 
tolerance and inhibits the proliferation and function of T cells, by repressing TCR signaling 
and inducing genes that impair T cell function such as basic leucine zipper transcription factor 
(BATF). In vitro studies show that blocking the PD-1 pathway allows T cell exhaustion to be 
partly overcome by enhancing the proliferation of CD8+ and CD4+ T cells and promoting 
cytokine production101,102.  
CTLA-4 is an inhibitory receptor structurally characterized by a type I transmembrane 
protein with a single V-set immunoglobulin extracellular domain, a transmembrane region 
and a cytoplasmic region that contains an ITIM domain. This receptor was firstly described 
on T cells, but recently it has also been shown to be present on monocytes and mature DCs103. 
In T cells the levels vary according to the cell subtype and activation status. Intracellular 
CTLA-4 is detectable only at low levels in naïve human T cells, whereas human T cell clones 
and memory T cells show significant amounts of this receptor. Upon activation, CTLA-4 is 
rapidly expressed on the cell surface, lasting longer on the membrane of memory cells 
compared with naïve cells. Tregs show high amounts of intracellular CTLA-4 and 
constitutively express this receptor at the cell surface104. The total amount of CTLA-4 in 
activated peripheral T cells is comparable to CD28; however its levels at the cell surface are 
significantly lower. Therefore, CTLA-4 is primarily localized in intracellular compartments 
[such as trans Golgi network (TGN), endosomes, secretory granules and lysosomal vesicles] 
whose surface expression is tightly regulated by restricted trafficking to the cell surface and 
rapid internalization. This is important because minor changes in surface expression levels 
could have major effects on the outcome of T-cell activation105. CTLA-4 is localized in the 
TGN, where it binds to the transmembrane adaptor T-cell receptor interacting molecule 
(TRIM) and/or the clathrin adaptor protein-1 (AP-1). Upon T-cell activation, CTLA-4 is 
translocated to the cell surface, promoted by the presence of TRIM. Alternatively, binding to 
clathrin AP-1 mediates direct transport to lysosomal compartments. In order to keep CTLA-4 
on the cell surface, the Y201 residue must be phosphorylated by Src kinases. Subsequent 
dephosphorylation at Y201 allows the binding of the clathrin AP-2 and the rapid 
	  





internalization and transport of CTLA-4 to endosomal or lysosomal compartments. 
Internalised CTLA-4 might be degraded quickly or recycled to the cell surface via secretory 
lysosomes106. CTLA-4 has a key role in controlling and dampening T cells after they have 
received co-stimulatory signals. By binding to CD80/CD86, CTLA-4 diminishes T-cell 
responses and helps bring an inflammatory response back down to homeostatic levels, 
establishing the peripheral immune tolerance. This idea was even clearer when the CTLA-4 
knockout mouse phenotype was described to develop a lymphoproliferative disease107. 
Moreover, some polymorphisms in the CTLA-4 gene have been associated with susceptibility 
to different autoimmune diseases (type 1 diabetes, multiple sclerosis, rheumatoid arthritis, 
Graves’ disease, colitis and systemic lupus erythematosus). Several mechanisms have been 
reported for CTLA-4 inhibition of T-cell activation. First, by direct competition for CD28 
binding to CD80 and CD86. Second, through the disruption of CD28 localization at the 
immunological synapse. Finally, by interference with the expression or composition of lipid 
rafts on the surface of T cells. When T cells become activated, CTLA-4 binds to CD80 and/or 
CD86, leading to decreased IL-2 production, inhibition of proliferation and negative 
modulation of TCR signalling. Besides CD8+ T effector cells, CTLA-4 seems to have an 
important role on two major subsets of CD4+ T cells, with distinct effects: downregulation of 
Th cells and enhancement of Tregs. Therefore, Treg cells constitutively express high levels of 
CTLA-4; in an in vitro experimental model of colitis blockade of CTLA-4 specifically 
affected the suppression capacity of Tregs108. Additionally, CTLA-4 has a key role in CD4+ 
T-cell differentiation. CTLA-4-deficient mice and Balb/c mice treated with anti-CTLA-4 
monoclonal antibody (mAb) showed an increased Th17 differentiation and IL-17 
production109. Given the fact that CTLA-4 is an inhibitory receptor that regulates T cell 
responses, it has become a potential therapeutic target. Preclinical studies, using anti-CTLA-4 
mAb, demonstrated significant antitumor responses in vitro and in vivo models, such as, 
lymphoma110, prostate cancer111, colon carcinoma and fibrosarcoma. Interestingly, only the 
animals that induced an endogenous anti-tumor response after tumor implantation, responded 
to the CTLA-4 treatment112. 
Although PD-1 and CTLA-4 are the best characterized inhibitory receptors associated with 
exhaustion, several other receptors have also been shown to impair T-cell responses during 
chronic infections, including CTLA-4, Tim-3, LAG-3, 2B4 (CD244, non-MHC binding 
natural killer cell receptor), among others. These inhibitory receptors act synergistically, but 
	  





not redundantly, to establish T cell exhaustion that is ultimately “tuned” by the availability of 
ligands in the environment113. Blockade of negative checkpoint receptors is a strategy to 
overcome the tumor-induced T cell dysfunction, and has emerged as a promising approach for 
treatment of cancers. As mentioned in the immunotherapy section, CTLA-4- and PD-1- 
blocking monoclonal antibodies are FDA approved for treatment of melanoma and lung 
cancer and are currently being tested in other malignancies.  
 
1.1.4. Tim-3 
Tim-3 was first described as a negative regulatory molecule important for dampening Th1 and 
Tc1 driven immune responses. This receptor is comprised of an N-terminal IgV domain 
followed by a mucin domain, a transmembrane domain and a cytoplasmic tail. In the IgV 
domain there are four non-canonical cysteines, which result in the formation of an unique 
binding cleft, that has been shown to be important for the binding of Tim-3 to 
phosphatidylserine and for the clearance of apoptotic bodies by macrophages and DCs. It is 
not expressed on the surfaces of naive T cells but emerges on the cell surface of fully 
differentiated CD4+ Th1 cells, and also on CD8+ T cells, Th17, Tregs, NK cells, 
macrophages, monocytes, DCs, mast cells and microglia. Tim-3, as one of the critical CD4+ 
Th1 cell surface molecules, may have multiple functions in regulating T cell responses114.  
 
1.1.4.1 Ligands 
Different molecules have been postulated as Tim-3 ligands, each with distinct roles. Galectin-
9 (Gal-9) was the first one described; it is a soluble molecule that is widely expressed and is 
upregulated by IFN-γ. It binds to Tim-3 amino-linked carbohydrates on the IgV domain and 
when it activates Tim-3 on Th1 cells, induces cell death115. High mobility group box 1 
(HMGB1) and phosphatidylserine (PtdSer) are two other ligands that bind to Tim-3 through a 
metal ion–dependent ligand-binding site in the hydrophobic FG-loop of the immunoglobulin 
variable domain. HMGB1 is a deoxyribonucleic acid (DNA)-binding protein that besides 
acting as a chromatin factor with roles in genome stability and the promotion of transcription 
in the nucleus, it has also key roles in inflammation, immune responses, DC differentiation, 
migration of inflammatory cell, and regulation of autophagy. In a recent study it was shown 
	  





that the regulation of nucleic acid–mediated innate immune responses by Tim-3 is dependent 
on HMGB1. HMGB1 consists of DNA-binding A and B boxes, as well as an acidic carboxyl 
terminus. Tim-3 actively competes with nucleic acids to bind the A box of HMGB1. As a 
receptor for HMGB1, Tim-3 impairs the HMGB1-mediated recruitment of nucleic acids into 
endosomes, a key step in the sensing of DNA by the innate immune system116. In addition, 
DCs are essential targets in efforts to generate therapeutic immunity to cancer; they interact 
with natural killer cells to promote their further activation and immunity to tumors through 
the release of HMGB1. Carcinoembryonic antigen-related cell adhesion molecule 1 
(CEACAM1) was recently described as a Tim-3 ligand, which facilitates the maturation and 
cell surface expression of Tim-3, and their interaction determines the tolerance-inducing 
function of Tim-3 and contributes to its inhibitory function. Interestingly, co-blockade of 
CEACAM1 and Tim-3 enhances the anti-tumor immune response in a tumor mouse model117. 
Finally, HLA-B-associated transcript 3 (Bat3) was shown to be a binding partner to the Tim-3 
intracellular tail. However, contrary to the previous ligands, it functions as an inhibitory 
receptor for Tim-3 function, since it protects Th1 cells from galectin-9 mediated cell death, 
and promotes both proliferation and pro-inflammatory cytokine production. Therefore, Bat3 
seems to represent an important novel repressor of Tim-3 signaling that protects Th1 
responses from Tim-3-mediated inhibition118. 
 
1.1.4.2 Role of Tim-3 on T cells 
It has been reported that Tim-3 negatively regulates Th1-mediated inflammatory diseases such 
as experimental autoimmune encephalomyelitis (EAE), type I diabetes, and acute graft-
versus-host disease (aGVHD). The blockade of the Tim-3–Tim-3L pathway in vivo 
exacerbates EAE and Type-1 diabetes119. Similarly, abrogation of Tim-3 signaling either with 
blocking antibody or by RNA interference increases the secretion of IFN-γ by activated 
human T cells120. In addition, Tim-3 is also involved in the induction of peripheral tolerance, 
since its blockade abrogates the development of tolerance in Th1 cells and Tim-3-deficient 
mice are refractory to induction of tolerance after high dose antigen administration121. More 
recently Tim-3 has emerged as a marker of T cell exhaustion and is over-expressed in 
impaired CD8+ T cells in various chronic viral infections and advanced cancer (Figure 
1.8)122. This finding is clinically relevant since it is possible to restore the function of these 
impaired CD8+ T cells by blocking the Tim-3-Tim-3L pathway123. Interestingly, upregulation 
	  





of Tim-3 has also been observed in PD-1+ CD8+ T cells in some tumor mice models, as well 
as, in blood of patients with advanced melanoma. In both cases, Tim-3+PD-1+ CD8+ cells 
represent the most impaired population of CD8+ T cells, exhibiting defects in proliferation 
and producing the least amount of IL-2, TNF, and IFN-γ. Furthermore, combined treatment 
with anti-Tim-3 and anti-PD-L1 or anti-PD-1 resulted in a much better response when 
compared with each blockade separately124,125. Interestingly, the majority of intratumoral 
FoxP3+ Tregs express Tim-3 and PD-1, are highly suppressive and are rarely observed in the 
peripheral tissues or blood of tumor-bearing mice. Moreover, the co-blockade of the Tim-3 
and PD-1 signaling pathways in vivo results in the downregulation of molecules associated 
with Tim-3+ Treg suppressor functions, suggesting that the potent clinical efficacy of co-
blocking Tim-3 and PD-1 signaling is a result of the reversal of T-cell exhaustion combined 





1.1.4.3 Role of Tim-3 on innate cells 
Tim-3 is constitutively expressed on innate immune cells including NK cells, macrophages, 
monocytes and DCs. On macrophages, Tim-3 is upregulated in response to stimuli, acting as 
an activation marker. However, blockade of the Tim-3 pathway during sepsis in vivo or 
downregulation of Tim-3 on macrophages in vitro led to enhanced macrophage activation, 
Figure 1.8. The role of Tim-3 on innate (DCs) and adaptive (T cells) immune cells122  
	  





thereby indicating that it is acting as an inhibitory receptor. Therefore, Tim-3 can be 
upregulated on macrophages in response to stimuli, but it may also act to suppress 
macrophage activity128. In regard to monocytes, stimulation with the toll-like receptor 4 
(TLR4) ligand LPS or the toll-like receptor 7/8 (TLR7/8) ligand R848 downregulates Tim-3 
expression, leading to an enhanced IL-12 expression129. Thus, increased Tim-3 expression on 
monocytes may act to suppress their activity, whereas reduced Tim-3 expression may be 
associated with monocyte activation. In such a scenario, increased Tim-3 expression and a 
failure in the downregulation of Tim-3 on macrophages/monocytes may be an indicator for 
dysfunctional macrophages/monocytes, as demonstrated previously for CD4+ and CD8+ T 
cells130. In addition, a recent study demonstrated that Tim-3 recognizes apoptotic cells 
through the FG loop in its IgV domain and is crucial for the clearance of apoptotic cells by 
phagocytes. Therefore, cross-presentation of dying cell-associated antigens was shown to be 
reduced by Tim-3 pathway blockade in vitro and in vivo131. Tim-3 was also studied in DCs 
and in the TME these cells up-regulate Tim-3 that interacts with the alarmin HMGB1, 
suppressing nucleic-acid-mediated innate immune responses. Remarkably, when Tim-3 
signaling was blocked using anti-Tim-3 mAb, chemotherapy was found to be more effective, 
suggesting that Tim-3 plays a role in tumor pathogenesis116.  
 
Two studies on the role of Tim-3 on NK cells from healthy donors were published presenting 
different conclusions. One of the studies showed that many cytokines, such as interferon-
alpha (IFN-α) and combinations of IL-12+IL-18 or IL-12+IL-15, could induce Tim-3 
upregulation on NK cells. Furthermore, NK cell IFN-γ production and cytotoxic ability were 
associated with high Tim-3 levels. These authors therefore concluded that Tim-3 might act as 
a marker of fully mature and functional NK cells. Moreover, when Tim-3 was cross-linked on 
NK cells with antibodies or encountered target cells that expressed its ligand Gal-9, it 
suppressed NK cell-mediated cytotoxicity, showing that Tim-3 also suppresses NK cell 
functions132. On the contrary, the second study demonstrated that Tim-3 was upregulated on 
human NK cells following activation and promoted IFN-γ production in response to Gal-9133. 
A negative regulatory role of Tim-3 on the activity of NK cells has been demonstrated in 
chronic hepatitis B infection where Tim-3 expression is upregulated on NK cells. This 
receptor suppresses NK cell function as this inhibition could be reversed by blockade of the 
Tim-3 pathway134. These data suggest that Tim-3 is a marker of NK cell activation, however 
	  





its overexpression may also restrain NK cell function in certain situations. 
 
1.1.4.4 Role of Tim-3 on nonhematologic cells 
Tim-3 is also expressed on cancer cells and in other nonhematologic cells. Tim-3 is expressed 
in endothelial cells in lymphoma resulting in local immune suppression and, consequently, 
adverse clinical features of lymphoma135. Furthermore, Tim-3 is expressed at a higher levels 
in clinical cervical cancer cells compared to cervical intraepithelial neoplasia (CIN) and 
chronic cervicitis controls, and that this expression may promote metastatic potential in 
cervical cancers136.  
 
1.1.4.5 Tim-3 as a therapeutic target 
To date, few studies have extensively assessed the mechanism of action of anti-TIM3 mAb 
against tumors. In a fibrosarcoma mice model, the combination of anti-TIM3 and anti-PD-1 
mAbs significantly suppressed established tumor growth and even resulted in cures in a small 
proportion of these treated mice123,124,137. Interestingly, Tim-3 blockade in combination with a 
vaccine stimulates potent anti-tumor responses against established melanoma. This effect 
occurs via NK cell-dependent mechanisms and not through T-cell action138. Of importance, 
anti-TIM3 alone or in combination with anti-PD-1 was well tolerated, and no overt 
autoimmunity was observed in treated tumor-bearing mice.  
 
1.1.5. NK cells 
NK cells are innate immune cells with natural cytotoxicity against tumor cells. These cells are 
distributed throughout lymphoid and nonlymphoid tissues in different proportions, 
representing only 2% to 18% in human peripheral blood with a turnover of two weeks. NK 
cells are generally divided into two subsets according to the expression of CD56 e CD16 
receptors and function. The cytotoxic subset, characterized by CD56dimCD16+, corresponds to 
90% of NK cells present in the peripheral blood and spleen. On the contrary, the cytokine 
producer subset, CD56brightCD16–, is the majority of NK cells in the lymph nodes and tonsils, 
and comprises only 10% of the peripheral blood population. Different chemokines and their 
	  





respective receptors are responsible for NK cell mobilization and homing. Therefore, 
CD56brightCD16– NK cells express C-C chemokine receptor type 7 (CCR7) that induces their 
homing to lymph nodes. Moreover, the CD56dimCD16+ human NK cell subset expresses CXC 
chemokine receptor 1 (CXCR1), also called interleukin 8 receptor alpha (IL-8Rα), which is 
important for recruitment of NK cells into peripheral inflammatory sites139. 
 
1.1.5.1 NK-cell differentiation and education  
The precursor NK (pNK) cell is generated from multipotent haematopoietic precursors, 
including haematopoietic stem cells and early lymphoid precursors. NK cells are derived from 
CD34+ pNK cells through discrete stages of development, such as pNK, immature NK (iNK) 
and mature NK, and are characterized by the sequential acquisition of surface receptors and 
effector function. As the cells differentiate from pNK to iNK cells, the expression of Fms-like 
tyrosine kinase 3 (Flt3) and interleukin-7 receptor alpha (IL-7Rα/CD127) decreases, whereas 
the expression of IL-2R beta chain (IL-2Rβ), CD2 (cell adhesion molecule) and 2B4 
increases. The final maturation of NK cells is characterized by the acquisition of activating 
and inhibitory receptor expression. The acquisition of mature NK cell function is also 
dependent on the presence of EOMES and T-bet that induce the expression of the cytolytic 
machinery (for example, perforin and granzymes) and IFN-γ. The next step of NK cell 
maturation is called “education or licensing”, when inhibitory NK-cell receptors engaged by 
self MHC molecules generate NK cells that are tolerant to self and have the capacity to 
“sense” MHC class I expression levels on target cells that may vary during infection, 
transformation or stress. Nevertheless, around 10-20% of NK cells do not express any known 
inhibitory receptors for self MHC class I molecules and consequently do not interact with self 
MHC molecules. These cells, could be potentially harmful as they fail the inhibition by self 
MHC class I molecules, however they have a reduced response to stimulation via activating 
receptors. Therefore, mature NK cells (CD11bhiCD4+9b+) found in the periphery include 
educated, fully responsive NK cells stimulated via through activating receptors and self-
tolerant NK cells, but also hyporesponsive NK cells140.  
After the maturation process NK cells leave the site where they are generated and traffick to 
other tissues, such as the secondary lymphoid organs, lungs, liver and gut. In these different 
sites, according to their activation status, they can be “resting” NK cells, where they lack 
	  





signs of recent activation or “activated” NK cells, that are highly efficient and bear markers of 
recent stimulation140.  
 
1.1.5.2 NK cell function 
The activity of NK cells is a result of a dynamic balance between activating and inhibitory 
receptors that allows them to be ready to kill target cells or to be self-tolerant to avoid 
autoimmunity141 (Figure 1.9). The activating receptors detect the presence of diferent types of 
ligands on cells in “distress” including, stress-induced self-ligands (MICA, MICB and UL16 
binding protein - ULBP), infectious nonself ligands and TLR ligands. These activating 
receptors include NKG2D, natural cytotoxicity receptors (NCRs – such as natural killer p30, 
p44 and p46 - NKp30, NKp44 and NKp46, respectively) and DNAM-1. Furthermore, as NK 
cells also express the low-affinity Fc receptor CD16, they are able to exert antibody-
dependent cell cytotoxicity. Some of these activating cell surface receptors stimulate protein 
tyrosine kinase-dependent pathways through reversible associations with transmembrane 
signaling adaptors. Others, like NKG2D, are not directly coupled to immunoreceptor tyrosine-
based activation motifs and are well associated with transmembrane signaling adaptors (like 
DNAX-activating protein 10 and 12 - DAP10 and DAP12), as well as integrins and cytokine 
receptors. IL-2 is an important regulator of the expression of activating receptors, inducing 
some of them (NKp44 and CD69) and up-regulating others (NKp30, NKG2D and partially, 
NKp46). Inhibitory receptors detect the absence of constitutively expressed self-molecules on 
susceptible target cells (HLA class I molecules) allowing the NK cells to target specifically 
those cells (“missing-self theory”). In fact, tumor cells with low HLA class I expression 
(result of immunoediting), are the best targets for NK cells142. The inhibitory receptors belong 
to two main categories: the killer cell immunoglobulin-like receptors (KIRs) and lectin-like 
CD94-NKG2A. A common feature of these inhibitory receptors is the presence of ITIMs, that 
are phosphorylated on their tyrosine residues and recruit lipid or tyrosine phosphatases after 
ligand binding. The tyrosine phosphorylation status of several signaling components that are 
substrates for both protein tyrosine kinase and protein tyrosine phosphatases is thus key to the 
propagation of the NK cell effector pathways142. 
 
	  









The intensity and the quality of NK cell cytotoxic and cytokine responses depend on the 
microenvironment, the presence/absence of cytokines and the interaction with some immune 
(DCs, CD4+ T cells and Tregs) and non-immune (endothelial cells and fibroblasts) cells. NK 
cells need to be “primed” for full activation, as resting human peripheral blood NK cells are 
poorly effective. IL-2 is a key cytokine for NK cell activation, promoting their proliferation, 
cytotoxicity and cytokine secretion. NK cells are activated in the lymph nodes through T-cell-
derived IL-2 production. Type I IFN, IL-12, IL-18 and IL-15 are other well known activators 
of NK cell effector function139.  
NK cells are mainly cytotoxic lymphocytes that act through direct cytotoxicity and/or by 
secreting some cytokine and chemokines. One of the mechanisms used by these cells is 
Figure 1.9. Different scenarios of NK cell activity according to the 
balance between activating and inhibitory receptors141. 
	  





exocytosis of granules containing perforin and various granzymes in the immunological 
synapse, leading to the perforation of target cells and subsequent apoptotic death. The NK cell 
immunological synapse is the dynamic interface formed between an NK cell and its target 
cell. The formation of the NK cell immunological synapse involves several distinct stages, 
from the initiation of contact with a target cell to the directed delivery of lytic granule 
contents for target cell lysis143. Progression through the individual stages is regulated, and this 
tight regulation underlies the precision with which NK cells select and kill susceptible target 
cells, including tumor cells that they encounter during their surveillance of the body. Another 
mechanism of cytotoxicity involves the engagement of TNF receptor superfamily (TNFRSF) 
members, such as Fas receptor (FasR), TNF-related apoptosis-inducing ligand (TRAIL) 
receptors and TNF receptor 1 (TNFR1), on tumor cells by the corresponding ligands (FasL, 
TRAIL and TNF) expressed on or secreted by NK cells. Furthermore, NK cells have a high 
capacity to secrete a variety of cytokines and chemokines, TNF, GM-CSF and macrophage 
inflammatory protein-1α (MIP-1α), and are considered as the major source of IFN-γ in 
vivo144. 
 
1.1.5.3 NK cell immunological memory 
Adaptive immune cells, such as T cells, have the ability to learn from previous experience, 
such as a single encounter with many pathogens that exist, and to react with a specific and 
strong immune response. The result is immunological memory that confers long-lasting 
protection. Interestingly and unexpectedly, there is recent evidence showing that NK cells 
could be key players in the persistence of immunity, due to immunological memory. 
Therefore, a subset of liver NK cells were able to mediate an “adaptive-like” immune reaction 
of hapten-specific contact hypersensitivity in mice lacking T and B cells145. In a different 
study, mouse NK cells expressing the activating receptor lymphocyte antigen 49H (Ly49H), 
which recognizes the MCMV m157 protein, were shown to clonally expand and subsequently 
contract while leaving a few long-lived cells able to mount a “secondary” response. 
Furthermore, these cells were found to be active and protective when transferred to naive 
mice. In fact, following MCMV infection, NK cells can therefore give rise to a population of 
long-lived cells with an intrinsic ability to exhibit enhanced effector functions when 
restimulated146. Moreover, NK cells activated in vitro by cytokines (IL-12/IL-18) and 
	  





adoptively transferred in vivo also display some “memory-like” properties with an enhanced 
ability to secrete IFN-γ147. Altogether, these results prompt research into the mechanisms that 
allow the boosted effector function of NK cells to be maintained across cell divisions, in 
particular the epigenetic marks associated with various stages of these cells’ activation. 
 
1.1.5.4 NK cell surveillance  
NK infiltration in tumor tissue is associated with better prognosis in squamous cell lung, 
gastric and kidney carcinomas95,148,149, while low activity of peripheral blood NK cells is 
associated with increased risk of cancer150. Moreover, a remarkable increase in survival from 
relapse in myeloid leukaemia was reported for patients lacking HLA class I ligands for donor-
KIR who received alloreactive NK cells in the course of allogeneic haematopoietic stem cell 
transplantation. This observation is clear evidence for the beneficial role of NK cells in the 
control of human malignancies151. Furthermore, it has been shown that high doses of IL-2 
induces clinical responses in advanced melanoma patients, through T cell and also NK cell 
activation54. 
NK cells recognize tumor cells through the interaction with their activating and inhibitory 
receptors. The most important NK cell activating receptors that sense aberrant cells are 
NKG2D, NCRs (NKp30 and NKp46) and DNAM-1. NKG2D is a key receptor in the NK 
cell–mediated immune surveillance, as it has been shown to contribute to tumor progression 
in the context of impaired NKG2D function152. In addition, different NKG2D haplotypes are 
correlated with the natural cytotoxic activity of peripheral blood lymphocytes and the risk of 
cancer development in humans153. NKp30 is also important in NK-cell mediated antitumor 
activity. It mediates NK-DC crosstalk and promotes tumor cell recognition and lysis. 
Therefore, the loss of NKp30 expression correlates with impaired NK cell cytotoxicity and 
shorter survival in patients with acute myeloid leukemia (AML)154. Moreover, the lack of 
NKp46 failed to control effectively the growth of transplanted melanoma in a mice model155. 
DNAM-1 is an adhesion molecule with two well-known ligands, CD155 and C122 that are 
expressed by different tumors, including melanoma. Its relevance in the NK cell-mediated 
immuno-surveillance was shown in DNAM-1 knockout mice156. 
 
	  






Immune surveillance is an important mechanism in controlling cancer progression; however it 
also induces immunoselection, where malignant cells with changes in NK cell-activating 
ligands are able to escape NK cells. Therefore, genetic instability of tumor cells might lead to 
mechanisms of immunosubversion including, among others, upregulation of MHC molecules 
that deliver strong inhibitory signals, and impaired expression of activating receptors and 
modulation of cellular ligands that engage activating immunoreceptors on cytotoxic cells, 
including NK cells and cytotoxic T lymphocytes and promote exhaustion. The shedding of 
NKG2DL from the surface of tumor cells is a good example of this last mechanism.  
NKG2D is mainly expressed on NK and CD8+ T cells and this expression is regulated by 
cytokines; IL-15 enhances NKG2D surface expression, while TGF-β downmodulates 
NKG2D. NKG2D-NKG2DL ligation causes phosphorylation of DAP10 that leads to 
activation of NK cells and costimulation of T cells. MICA/MICB and the ULBP constitute the 
two families of NKG2DL, that are induced by various forms of cellular stress such as viral 
infection, DNA damage or ultraviolet (UV) radiation. They are expressed in many tumors in 
humans157, however MICA and/or MICB are also detected on non-tumoral tissues, such as the 
gastrointestinal ephitelium and tissues exposed to autoimmune attack. The expression of 
NKG2DL varies according to the type of tumor as well as to the stage of the tumor. Invasive 
tumors have elevated levels of serum sMICA because as disease progresses, tumor cells 
express more proteases, that are responsible for surface NKG2D ligands shedding. 
Interestingly, it has been shown that membrane-bound NKG2D ligands stimulate immunity 
whereas soluble NKG2DL impair host immunity, as recently demonstrated in the transgenic 
mice model96. Tumor cells release NKG2DL in a soluble form which critically affects tumor 
immunogenicity by downregulating the expression of activating receptors and dampening the 
activating signals for NK and T cells. Therefore, tumor shedding of MIC and sustained 
exposure of NK cells to NKG2DL systemically impairs the responses of CD8+ T cells and NK 
cells157,158. 
Finally, an important phenomenon mentioned previously, is progressive NK cell exhaustion 
in the context of various tumors, as a consequence of continuous exposure to certain target 
antigens. Therefore, NK cells exhibited strong anti-tumor functions and cytokine production 
	  





early after adoptive transfer, however, starting at day 5 post-transfer, NK cells exhibited weak 
IFN-γ production and cytotoxicity, despite being present at the tumor sites98.  
 
1.1.5.6 NK cell-based therapies 
NK cells preferentially target tumor cells with low HLA class I expression. This alternative 
recognition system of NK cells, which benefits from HLA downregulation on tumor cells, 
combined with their innate antitumor potential, offers a valid therapeutic option. In addition, 
some anti-tumor strategies, such as chemotherapy and radiotherapy, by forcing the expression 
of ligands for DNAM-1 and NKG2D on tumor cells, make them more prone to be targeted by 
NK cells. Therefore, NK cells are an attractive alternative, or potential adjuvant, to T cell-
based immunotherapy159. There are several strategies to optimize the NK-cell anti-tumor 
activity including, activation of endogenous NK cell response, adoptive transfer of 
alloreactive NK cells, blocking inhibitory signals and blocking immunosuppressive 
mechanisms in tumors susceptible to NK lysis142.  
NK cell dysfunction has been reported in different types of tumors, thus exogenous NK 
activators, such as IL-2, IL-12, IL-15, IL-18, IL-21 and type I interferons, may be used to 
improve the anti-tumor NK cell response. High dose IL-2 has been shown to be able to 
activate and expand NK cell populations in some cancer patients, and is translated into 
clinical responses; however, this treatment is limited by severe side effects. IL-15 is a 
promising candidate for activating NK cells because IL-15 is indispensable for NK cell 
maturation. When combined with chemotherapy, the administration of IL-15 potentiated 
antitumor effects160.  
Adoptive transfer of alloreactive NK cells consists of NK cell isolation from the tumor (or 
their production in vivo), their expansion and introduction to patients. The first trial involving 
adoptive transfer of NK cells, using a combination of ex vivo-expanded autologous 
lymphokine-activated killer cells and exogenous IL-2, did not achieve better clinical results 
than high-dose IL-2 alone161. Unlike autologous cell transfers, allogeneic adoptive cell 
transfers have the benefit of mismatched KIR/KIR ligands between the host and donor NK 
cells, although these therapies run a great risk of GVHD that can cause severe damage to host 
tissues. An infusion of haploidentical allogeneic NK cells has also been applied to patients 
with poor prognosis in Hodgkin’s lymphoma and various solid tumors, such as melanoma and 
	  





renal cancer, with interesting clinical results162. While NK cells may achieve clinical 
responses, certain issues need to be considered. First, the type of NK cells to be infused must 
be considered, as the use of distinct NK cell subsets or protocols for NK cell activation ex 
vivo might interfere with the outcome. Second, the criteria for donor selection are crucial. For 
this reason, KIR genotyping and phenotyping must be performed, the size of the alloreactive 
subset must be measured, and the NKG2D and/or NCR haplotypes must be determined. 
Third, the conditioning regimen of patients before the adoptive transfer, which may vary 
depending on the immune status of the disease being treated. Fourth, clinical indication must 
be appropriately selected on the basis of the susceptibility of target cells to lysis163.  
The selective blockade of inhibitory receptors (CD94/NKG2A and KIRs) and upregulation of 
activating receptors (NKG2D) has been developed to enhance the effect of NK cell 
immunotherapy. As an example, the human monoclonal antibody called 1-7F9, that prevents 
signaling via KIRs (KIR2DL1, KIR2DL2 and KIR2DL3) was developed to increase NK cell-
mediated cytotoxicity against tumors expressing HLA-C164. Furthermore, It has become 
increasingly clear that the TME plays a crucial role in the impairment of the immune response 
and in the development of many overlapping mechanisms that create an immunosuppressive 
microenvironment. It has been reported that tumor-associated NK cells display a modified 
phenotype, thereby supporting the notion that tumor-induced alterations of activating NK cell 
receptor expression may hamper immune surveillance and promote tumor progression. Given 
the important immunomodulatory effects of the TME, it stands to reason that it may represent 
a therapeutic target that can be manipulated to improve the anti-tumor immune response. 
Thus, the first clinical interventions that aim to target the microenvironment to enhance tumor 
immunity are under active evaluation165. 
 
In summary, NK cells are “innate killers” but they are not just “innate killers”. The scientific 
community is aware of that, and now the focus is to try to unveil the processes orchestrating 









1.2. Rationale, Hypothesis and Aims 
 
1.2.1. Rationale 
Despite the anti-tumor response, particularly the presence of anti-tumor immune cells (T cells, 
NK cells and NKT cells) infiltrating into the tumor stroma, many tumors continue to grow, 
including melanoma. Two main interrelated phenomena have been described to justify that 
fact: the tumor cells can create an immune tolerant microenvironment and the anti-tumor cells 
can be dysfunctional. The underlying mechanism for this anti-tumor immune cell dysfunction 
or “exhaustion” is not well understood; however It is postulated that the TME, enriched in 
immunosuppressive molecules (TGF-β, IL-10, sMICA) and cells (TAM, MSDC, Tregs) may 
contribute to a weakened anti-tumor immune response. This exhausted phenotype was firstly 
described for T cells in the context of chronic infectious diseases and now also in different 
types of cancer, particularly in melanoma. This phenotype is characterized by early loss of 
proliferative capacity, cytotoxic potential, and the ability to produce IL-2, as well as, 
upregulation of inhibitory receptors, including CTLA-4, PD-1, Tim-3, among others. Besides 
T cells, studies are starting to evaluate this phenotype in NKT cells, however nothing is 
known about exhaustion in NK cells.  
NK cells are large granular lymphocytes with natural cytotoxicity against tumor cells. Their 
activity is a result of the balance between activating and inhibitory receptors. Activating 
receptors (NKG2D, NKp30, NKp44, NKp46) detect the presence of ligands on cells in 
‘distress’. Inhibitory receptors (NKG2A and KIRs) gauge the absence of constitutively 
expressed self-molecules on susceptible target cells (HLA class I molecules), targeting 
specifically those cells (“missing-self theory”). Therefore, tumor cells with low HLA class I 
expression (as a result of immunoediting), are the best targets for NK cells. 
TIM-3 is not expressed on the surface of naive T cells but emerges on the cell surface of fully 
differentiated CD4+ Th1 cells, and also in CD8+ T cells, Th17, Tregs, NK cells, macrophages 
and DCs. It negatively regulates Th1-mediated inflammatory diseases such as experimental 
autoimmune encephalomyelitis and acute graft-versus-host disease, and is also a marker of T 
cell exhaustion. However, nothing is known about the role of Tim-3 in NK cells, specifically 
whether it is a marker of exhaustion. 
	  






We first hypothezise that, as melanoma progresses, NK cell gradually develop a functional 
profile of exhaustion, similar to T cells, as a consequence of a more immunossupressive 
microenvironment. TGF-β, MICA or HMGB1 are present in the TME and are potential 
players in the mechanism of induction of NK cell exhaustion. We predict that high expression 
of any of these three molecules in the plasma of melanoma patients is associated with worse 
prognosis. Tim-3 has been described as an inhibitory receptor in T cells in the context of 
advanced cancers; however its role in NK cells from HD is still controversial, and it has not 
been studied in the context of melanoma. We believe Tim-3 negatively regulates NK cell 
function in melanoma patients, and that its blockade reverses NK cell exhaustion in this 
context. Lastly, ipilimumab is able to reverse T cell exhaustion, that translates into clinical 
responses. Even though CTLA-4 has little expression on NK cells, we believe that 
ipilimumab has, directly or indirectly, an impact on the NK cells’ exhaustion phenotype. 
 
1.2.3. Specific aims  
1. To characterize the phenotype and function of NK cells from melanoma patients.  
§ To characterize the phenotype and function of NK cells from advanced melanoma 
patients in comparison with healthy donors (CHAPTER 2). 
§ To analyze the phenotype and function of NK cells from early stage melanoma 
patients (stage I, II and III) and determine how they relate with well-known prognostic 
factors including thickness, ulceration and mitotic index (CHAPTER 3).  
2. To identify potential inducers of NK cell exhaustion as prognostic markers. 
§ To measure the expression of sMICA, TGF-β and HMGB1 in the plasma of melamona 
patients and determine how it relates with prognosis (CHAPTER 3). 
3. To define the role of Tim-3 expression in NK cells from advanced melanoma patients. 
§ To crosslink Tim-3 on NK cells from advanced melanoma patients in comparison with 
healthy donors to assess its role in modulating NK cell function  (CHAPTER 4). 
	  





4. To study the effect of checkpoint blockade on the NK cell phenotype and function in the 
context of advanced melanoma patients.  
§ To inhibit Tim-3 in order to modulate NK cells function in advanced melanoma 
patients (CHAPTER 4). 

























CHAPTER 2:  
NK CELLS FROM ADVANCED MELANOMA PATIENTS 
DISPLAY AN EXHAUSTED PHENOTYPE 
 
2.1. Introduction 
Melanoma is the most aggressive type of skin cancer; it accounts for less than 2% of all skin 
cancers, but corresponds to more than 70% of their deaths8. In fact, melanoma responds 
poorly to systemic chemotherapy, and the 2-year OS was until recently around 15-20%. 
However, new therapeutic options are improving response rates and OS35,36.  
One such intervention is ipilimumab35, a monoclonal antibody against CTLA-4, a negative 
regulator that is upregulated on exhausted T cells in cancers and chronic infections166. The 
exhaustion phenotype has been described for T cells as a state of cellular dysfunction that 
arises as a consequence of continuous and chronic stimulation by viral or tumor antigens, as 
well as by immunosuppressive cytokines. It is characterized by a progressive and stepwise 
process of cell dysfunction, where IL-2 production and proliferative ability are the first 
effector activities to be extinguished, followed by cytotoxic activity (decreased production of 
perforin and granzymes), whereas the ability to produce IFN-γ is more resistant to 
inactivation90. In addition, as T cells acquire this exhausted phenotype, they start expressing 
some inhibitory receptors91,92, including CTLA-4167,168 , PD-1169 and Tim-393, while losing 
some activating receptors, such as CD44 and CD69. Furthermore, lower levels of the 
transcription factors T-bet and Eomes are also observed91. Besides T cells, new studies are 
starting to check this phenotype in NKT cells, however nothing is known about exhaustion in 
NK cells.  
NK cells are large granular lymphocytes with natural cytotoxicity against tumor cells. Their 
activity is a result of the balance between activating and inhibitory receptors. Activating 
receptors (NKG2D, NKp30, NKp44, NKp46) detect the presence of ligands on cells in 
‘distress’. While inhibitory receptors (NKG2A and KIRs) gauge the absence of constitutively 
expressed self molecules on susceptible target cells (“missing self theory”)139. Accordingly, 
	  





NK cell infiltration in tumor tissue is associated with better prognosis95,148,149, while low 
activity of peripheral blood NK cells is associated with increased risk of cancer150. These 
findings have prompted interest in the development of cancer therapies based on NK cells, 
such as NK cell adoptive transfer or targeting of NK cell inhibitory receptors170.  
In this study, we aimed to characterize the phenotype and function of NK cells from advanced 
melanoma patients. For this purpose we characterized the phenotype and function of NK cells 
from advanced melanoma patients in comparison with healthy donors. We found that NK 
cells from these subjects were functionally impaired/exhausted, opening exciting avenues for 
new therapies targeting NK cells in tumor immunotherapy. 
 
2.2. Material and Methods  
Human samples: Blood samples from healthy donors (HD) were purchased from the New 
York Blood Center. Blood samples were obtained under the Interdisciplinary Melanoma 
Cooperative Group Institutional Research Board (IRB) approved protocols (#H10362) from 
50 untreated melanoma patients (melanoma donors – MD; stages III/IV). The study was 
approved by the Institutional Research Board at NYU in accord with a Federalwide 
Assurance approved by the Department of Health and Human Services, and all patients 
provided informed written consent at the time of enrollment. 
Reagents: For staining - Tim-3 antibody used for staining experiments was purchased from 
R&D. Anti CD279 (PD-1) was purchased from BD Bioscience and anti-CTLA-4 was 
purchased from LifeSpan Biosciences. To check the purity of selected NK cells they were 
stained with antibodies to CD56, CD16, CD3, CD14 and CD19 purchased from Biolegend. 
Anti-CD25 was obtained from Miltenyi, and anti-CD122, anti-CD132, anti-CD107a-FITC 
(fluorescein isothiocyanate) and anti-IFN-γ-FITC antibodies were purchased from Biolegend. 
Anti-NKG2D, anti-NKp46, anti-DNAM-1, anti-KIR3DL1 and anti-KIR2DL3 antibodies (BD 
Bioscience) were used as indicated by the manufacturer. Anti-Eomes and anti-T-bet were 
purchased from eBioscience.  
For stimulation - the cytokines rhIL-2, rhIL-12, rhIL-15 and rhIL-18 were purchased from 
R&D systems.  
	  





Peripheral blood mononuclear cells (PBMCs) purification: Blood was slowly layered on 
top of Ficoll-Paque and then spun at 2200 rpm, for 20 min, with low brake and slow 
acceleration. After spinning, the white blood cells (WBC) layer was removed and added to 
RPMI media (50mL total). It was spun again at 1600 rpm, for 8min, with normal brake and 
acceleration. The supernatant was aspirated, the pellet was resuspended in 50mL of RPMI 
(Roswell Park Memorial Institute) media and it was spun again. These two steps were 
repeated twice.  
NK cell purification: Peripheral blood mononuclear cells (PBMCs) NK-cell enrichment was 
performed by negative selection using Easy-Sep Human NK cell Enrichment Kit (StemCell 
Technologies) according to the manufacturer’s recommendations, obtaining more than 95% 
CD3-CD56+ populations. Cell suspension was prepared at a concentration of 5 x 107 cells/mL 
in phosphate-buffered saline (PBS) supplemented with 0.5% bovine serum albumin and 2 
mM ethylenediamine tetraacetic acid (EDTA) - MACS Buffer. EasySepTM Human NK Cell 
Enrichment Cocktail at 50 µL/mL cells was added to the cell suspension, mixed and incubated 
at room temperature (15 - 25°C) for 10 minutes. The mix was vortexed for 30 seconds. 
EasySepTM D Magnetic Particles at 100 µL/mL cells was added to the cell suspension, mixed 
and incubated at room temperature (15 - 25°C) for 5 minutes. MACS buffer was added to the 
cell suspension up to 2.5 mL, mixed and placed in the tube in the magnet. The desired fraction 
(cells in suspension) was then aspirated. 
Cell lines: K562 cells were cultured in complete media (RPMI-1640 - Life Technologies) 
supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, 
and 100 µg/ml streptomycin. K562 is a chronic myelogenous leukaemia cell line used as 
target cells in the cytotoxicity assay. 
Cell Staining and Flow Cytometry Analysis: Before staining, cells were washed twice with 
MACS Buffer. For surface staining, cells were incubated with specific antibodies for 30min at 
40ºC. For intracellular staining, cells were first fixed with 4% paraformaldehyde (PFA) for 
10min at room temperature, permeabilized with MACS buffer supplemented with 0.1% 
saponin and stained with specific antibodies for 30min at room temperature. Cells were then 
washed twice with MACS buffer and analyzed by fluorescence-activated cell sorting (FACS). 
Data analysis was performed using FlowJo software. 
	  





NK cell stimulation: For short term functional assays (cytotoxicity and IFN-γ production), 
purified NK cells were activated overnight in the presence of 1000U/mL of IL-2 complete 
media (RPMI-1640 - Life Technologies, Carlsbad, CA) supplemented with 10% FBS, 2mM 
L-glutamine, 100U/ml penicillin, and 100µg/ml streptomycin. For the long-term experiments 
and proliferation assays, NK cells were cultured in the same media and stimulated with 
200U/ml of IL-2. 
Cytotoxicity Assay: Purified NK cells were co-cultured with target cells at a 5:1 
effector/target ratio in combination with anti-CD107a (lamp-1) antibody (0.5µg/ml) and 
monensin 1000X. After a 4h incubation, CD107a expression on CD56+ cells was quantified 
by flow cytometry. 
IFN-γ  production assay: Purified NK cells were cultured for 4h in the presence of 1µg/ml of 
IL-12 and brefeldin A (BFA, 10µg/ml). After 4h cells were fixed with 4% paraformaldehyde 
(PFA) and permeabilized (0.1% saponin). Permeabilized cells were stained for intracellular 
IFN-γ and analyzed by flow cytometry.  
Proliferation assay: Purified NK cells were loaded with 2µM carboxyfluorescein 
succinimidyl ester (CFSE) and cultured in complete media supplemented with 200U/ml of IL-
2. After 6 days of culture, CFSE dilution was analyzed by flow cytometry as a measure of cell 
proliferation. 
Statistical analyses: Two tailed unpaired t test was used to compare parameters between 
healthy and melanoma NK cells. Each experiment was performed in duplicate.  
 
2.3. Results 
Advanced tumors are characterized by an environment that promotes T cell exhaustion92. 
Exhausted T cells are characterized by: 1) over-expression of inhibitory receptors such as 
CTLA-4 and PD-1; 2) downregulation of cytokine receptors, rendering them refractory to 
cytokine stimulation; 3) loss of function (cytotoxicity, cytokine production and proliferation); 
and 4) downregulation of T-bet and Eomes171. In metastatic melanoma, peripheral blood 
CD8+ T cells are functionally exhausted93; however, NK cell phenotype and function have not 
been evaluated in this context. 
	  





To determine whether peripheral NK cells from advanced melanoma patients display an 
exhausted phenotype, we examined whether they expressed features associated with T cell 
exhaustion. NK cells were purified from peripheral blood of advanced melanoma patients and 




Interestingly, melanoma donor NK cells downregulate the NK cell markers CD16 and CD56 
(Figure 2.2.A), and consequently display a decrease in the percentage of both CD56bright and 
CD56dim NK cell subsets (Figure 2.2.B).  
  
Figure 2.1. NK cells were purified from peripheral blood. The plot on the left represents the gate on NK 
cells purified from peripheral blood from a melanoma patient. The other three plots show >95% of purity in 
the NK cell negative selection (> 95% are CD56+ CD3- CD14- CD19- cells).  
	  







We then measured the expression of activating and inhibitory receptors in NK cells from MD 
and HD. Clearly, NK cells from MD expressed higher levels of inhibitory receptors 
(KIR3DL1 and KIR2DL3) (Figure 2.3.A) and lower levels of activating receptors (NKG2D, 







Figure 2.2. NK cells from advanced melanoma patients downregulate CD56 and CD16 receptors. (A) 
The graph represents the percentage of CD16+ (left panel) and CD56+ NK (right panel) cells in healthy 
donors (n=13) and melanoma patients (n=11). (B) The plot shows the percentage of each NK cells’ subset 
(CD56dim and CD56bright) in total NK cells from healthy donors (n=34) and melanoma patients (n=24). 
	  

























































Figure 2.3. MD NK cells up-regulate inhibitory receptors and down-regulate activating receptors. (A) 
Graphs compare the expression of the inhibitory receptors KIR3DL1 (HD n=18; MD n=8) and KIR2DL3 
(HD n=26, MD n=12); (B) and the activating receptors NKG2D (HD n=25; MD n=12), NKp46 (HD n=20, 
MD n=11) and DNAM-1 (HD n=10; MD n=10), in peripheral NK cells purified from healthy donors and 
from melanoma patients. On the right panel, plots depicting the expression of NKG2D, NKp46, DNAM-1, 
KIR3DL1 and KIR2DL3 according to CD56 expression, in NK cells from a representative healthy donor 
and a representative melanoma patient. All experiments were performed in duplicate. 
	  
	  





We also evaluated PD-1 and CTLA-4 expression, however the levels were very low (1-3% of 
PD-1+ and CTLA-4+ NK cells) and there were no significant differences between MD and HD 
(Figure 2.4.A). Tim-3 is another immune checkpoint expressed by CD8+ T cells in advanced 
tumors, namely melanoma. However, the role of Tim-3 in NK cells in the same context 
remains unknown. Therefore, we first measured Tim-3 expression in MD NK cells. 
Compared to HD NK cells, MD NK cells expressed significantly higher levels of surface 




Secondly, we measured the levels of the three IL-2R chains [α chain (CD25; IL-2Rα), β 
chain (CD122; IL-2Rβ) and γ chain (CD132; IL-2Rγ)]. The expression of each subunit was 
measured in steady state conditions (day 0) and on days 2, 4 and 6 after IL-2 stimulation. HD 
or MD resting NK cells did not express significant levels of CD25 at rest. Interestingly, after 
IL-2 stimulation, HD NK cells upregulated CD25 to very high levels, whereas MD NK cells 
failed to do so (Figure 2.5.A). At rest, CD122 expression was similar in NK cells from 
healthy and melanoma subjects and decreased after IL-2 addition (Figure 2.5.A), while 
Figure 2.4. MD NK cells up-regulate the immune checkpoints CTLA-4, PD-1 and Tim-3. (A) The plots 
show the percentage of CTLA-4 (left panel) and PD-1 (right panel) expression in NK cells from healthy 
donors (n=10) and melanoma patients (n=5); (B) Graphs comparing Tim-3 expression in NK cells from 
healthy donors (HD; n=45) and melanoma patients (MD; n=41), represented as the percentage of Tim-3+ cells 
(left panel) and the MFI of the Tim-3+ population (right panel). All experiments were performed in 
duplicate. 
	  





CD132 expression was slightly higher in resting HD NK cells compared to MD NK cells. 
After IL-2 stimulation, both sources of NK cells showed an increase of this receptor, followed 
by a plateau phase and then a decrease, in expression of the CD132 receptor. However, the 
overall expression of CD132 on HD NK cells was substantially higher than that of MD NK 
cells (Figure 2.5.A). We next tested whether altered IL-2R expression translated into a 
differential response to IL-2 stimulation. While cytotoxicity was induced in both sources of 
NK cells, the levels increased more significantly over time in HD NK cells (Figure 2.5.B). 
Whereas IFN-γ production was induced by and increased in HD NK cells in response to IL-2, 
it did not change from baseline in the case of MD NK cells (Figure 2.5.B). Moreover, HD 
NK cells upregulated both KIR3DL1 and NKG2D, while MD NK cells did not (Figure 
2.5.C). We also measured the levels of the IL-15 receptor (IL-15R), another significant NK 
cell stimulatory molecule. Interestingly, IL-15R levels were significantly lower in MD NK 












Figure 2.5. NK cells from melanoma patients downregulate the expression of cytokine receptors, 
rendering them refractory to cytokine stimulation. (A, B and C) Freshly purified NK cells (HD n=12; 
MD n=5) were stimulated with 200U/ml of IL-2: (A) expression of CD25 (IL-2Rα; left panel), CD122 (IL-
2Rβ; middle panel) and CD132 (IL-2Rγ; right panel); (B) expression of Lamp-1 (CD107a; left panel) and 
IFN-γ (right panel); and (C) expression of KIR3DL1 (left panel) and NKG2D (right panel), were 
monitored every two days over 6 days (day 0, 2, 4 and 6) by flow cytometry. (D) The plot shows the 
percentage of IL-15R+ cells on NK cells from healthy donors (n=10) and melanoma patients (n=10). (A, 
lower panels) Baseline expression of CD25 (IL-2Rα; left panel), CD122 (IL-2Rβ; middle panel) and 
CD132 (IL-2Rγ; right panel). All experiments were performed in duplicate. 
	  





Finally, we determined whether NK cells from melanoma patients were functionally 
impaired, by assessing cytotoxicity, IFN-γ production and cell proliferation. We found that, in 
comparison with HD NK cells, MD NK cells failed to efficiently kill target cells as assessed 
by LAMP-1 expression, after stimulation by either IL-2 (p=0.0158) or IL-15 (p=0.04) 








Figure 2.6. MD NK cells are functionally impaired/exhausted – display a lower cytotoxic ability. (A) 
The percentage of Lamp-1+ NK cells from healthy (n=30) and melanoma donors (n=12) after a cytotoxic 
assay, using K562 cells as target cells, is shown. On the right panel, plot depicts the expression of Lamp-1 in 
NK cells purified from a representative healthy donor and a representative melanoma patient. (B) The plot 
shows the percentage of Lamp-1+ NK cells from healthy (n=11) and melanoma donors (n=10), stimulated 









In addition, MD NK cells produced less IFN-γ in response to IL-12 (p=0.0312) (Figure 
2.7.A), the combination of IL-12 and IL-18 (p=0.001), IL-15 (p=0.05) (Figure 2.7.B), or after 









Figure 2.7. MD NK cells are functionally impaired/exhausted – display a lower cytokine production 
ability. The percentage of IFN-γ+ NK cells stimulated with: (A) IL-12 cytokine (HD n=22; MD n=9); plot 
depicts the expression of IFN-γ in NK cells purified from a representative healthy donor (middle panel) and 
a representative melanoma patient (right panel); (B) IL-12+IL-18 or IL-15 cytokines (HD n=11; MD n=10); 









Finally, NK cells from melanoma patients lost their ability to proliferate when cultured with 
IL-2 (p=0.0024) (Figure 2.8.A), IL-12 (p=0.04), IL-15 (p=0.05) or IL-18 (p=0.01) (Figure 
2.8.B).  
 







Figure 2.8. MD NK cells are functionally impaired/exhausted – display a lower proliferative ability. 
The percentage of proliferating NK cells after 6 days of culture in presence of: (A) IL-2 cytokine (HD n=10; 
MD n=7); plot depicts the expression of proliferating NK cells purified from a representative healthy donor 
(middle panel) and a representative melanoma patient (right panel); (B) IL-12, IL-15 or IL-18 cytokines (HD 









The transcription factors T-bet and Eomes regulate the function of NK cells and a recent 
study showed that downmodulation of these transcription factors is a feature of NK cell 
exhaustion98. As expected, the expression levels of Eomes and T-bet are lower in NK cells 




These results clearly demonstrate that NK cells from advanced melanoma patients are 
functionally exhausted as shown by overexpression of inhibitory receptors and 
downregulation of activating receptors, an impaired response to IL-2 stimulation (possibly 
due to IL-2R downmodulation), defects in cytokine production, in proliferation and 
cytotoxicity, and a downmodulation of the transcription factors T-bet and Eomes. 
 
2.4. Discussion 
T cell exhaustion has been extensively studied in the context of chronic infectious diseases 
and different types of cancer, however, little is known about exhaustion of NK cells. 
Mamessier E. and colleagues have recently shown that NK cells from breast cancer patients 
depict some dysfunctional phenotype97; however our results provide the first demonstration 
that NK cells from advanced melanoma patients display the four main characteristics that 
define T cell exhaustion. Therefore, similarly to T cells, exhausted NK cells upregulate 
inhibitory receptors while downregulating IL-2R and consequently are unable to respond 
appropriately to IL-2 stimulation. In addition, they are functionally impaired (reduced 
Figure 2.9. MD NK cells downregulate the expression of T-bet and Eomes transcription factors. 
Graphs representing the mean fluorescence intensity (MFI) of T-bet and Eomes in NK cells purified from 
healthy (n=19) and melanoma donors (n=14). Representative plots are shown (Isotype control: black; HD: 










cytotoxicity, cytokine production and proliferation) and express reduced levels of activating 
receptors and the transcription factors Eomes and T-bet. Interestingly, this exhaustion 
phenotype is associated with a higher expression of the inhibitory receptor Tim-3, while there 
is almost no expression of CTLA-4 or PD-1.  
Nevertheless, since the late 1980s several studies have demonstrated the reversal of this 
tumor-associated NK cell phenotype after IL-2 stimulation, suggesting the absence of any 
inherent NK cell defect per se172,173. Recent studies have shown that different strengths of the 
activating stimuli are required for specific NK cell responses. Therefore, a low threshold for 
activation is needed for adhesion and release of chemokines, while degranulation and the 
release of other cytokines such as TNF-α require stronger activating stimuli, and IFN-γ 
displays the highest activation threshold for NK cell receptor cooperation. Consistently, some 
studies argue against an inherent NK cell defect in cancer patients and suggest the absence of 
sufficient activating signals for full NK cell effector function in the TME174. In our study, we 
have shown that even after IL-2 stimulation, NK cells from melanoma patients have a 
dysfunctional phenotype compared with healthy donors. Therefore, both theories may 
contribute to the explanation of the NK cell dysfunctional phenotype. On the one hand, TME 
does not provide the stimuli needed for a full NK cell activation, and hence it is possible to 
partially improve their function through cytokine activation. On the other hand, even with this 
ex vivo activation, it is not possible to reverse completely the NK cell exhausted phenotype.  
The exact mechanism of NK cell exhaustion is still unclear, however it is likely different from 
that seen in T cells, where there is a chronic stimulation and proliferation of a T cell clone 
against a specific antigen. It is possible that NK cells become exhausted due to systemic 
production of cytokines, or within the TME in response to specific ligands. Indeed, chronic 
stimulation with IL-2 and IL-15175,176 and shed MICA, a tumor-derived NKG2DL157,177, has 
been described to induce NK cell exhaustion. Exhausted T cells also upregulate CTLA-4 and 
PD-1, however we found no significant expression of these receptors in the membrane of MD 
NK cells.   
In conclusion, this study demonstrated for the first time that NK cells from advanced 
melanoma patients display an exhausted phenotype, similarly to T cells, including an 
upregulation of the exhaustion marker Tim-3. NK cells, therefore, represent promising 
therapeutic target that could enhance antitumor immunity with the potential to produce 
durable clinical responses.  
	  





CHAPTER 3:  
NK CELL PHENOTYPE AND SMICA ARE POTENTIAL 
PROGNOSTIC MARKERS IN MELANOMA PATIENTS 
 
3.1. Introduction 
Defects in NK cell activity have been described in patients with various metastatic 
malignancies, including melanoma94,95,96,97. Moreover, adoptive transfer of NK cells as an 
attempt to control tumor growth control has been associated with disappointing results. These 
results can be explained by a rapid acquisition of an exhausted phenotype, as it was shown in 
a mice model98. NK cell “exhaustion,” therefore, could explain the NK cell failure to contain 
tumor growth.  
Several factors can contribute to this NK cell exhausted phenotype, including cross-talk with 
immune cells (tumor-associated macrophages, myeloid-derived suppressor cells and T 
regulatory cells) and tumor cell-derived factors (i.e. TGF-β, VEGF, MICA and HMGB1)163. 
TGF-β is a cytokine that is produced by tumor cells that inhibit NK cells following chronic 
contact-dependent interactions between NK and tumor cells178. MICA is a MHC class I 
related molecule and is the NKG2DL, a NK cell activating receptor. It is expressed in the 
membrane of several types of cancer cells, and activates NK cells, when it binds to NKG2D. 
However, in the context of hypoxia, MICA is shed by these tumor cells and sMICA, on the 
contrary, leads to a downregulation of NKG2D on NK cells decreasing their cytotoxic 
ability157,158 ,165. HMGB1 is an endogenous dangerous signal that activates the immune system 
through different mechanisms. HMGB1 induces DC maturation while inhibiting NK cell 
cytotoxicity against DCs, thus playing key role in the crosstalk between NK cells and DCs. 
However, HMGB1 is a ligand of Tim-3, and the interaction between HMGB1 and Tim-3 may 
regulate tumor escape from the immune system116,179. We hypothesize that TGF-β, MICA and 
HMGB1 could be involved in that process and therefore would be highly expressed in 
advanced melanoma. 
	  





In this study, we aimed to evaluate NK cell phenotype and function as a consequence of 
progressive melanoma. For this purpose, we characterized the phenotype of NK cells in 
different phases of tumor progression and related it to prognostic factors. In addition, we 
quantified the expression of TGF-β, MICA and HMGB1 in the plasma/sera of our main 
cohort and of an independent validation cohort. These data demonstrated that NK cells 
become progressively exhausted in the context of melanoma progression and that targeting 
NK cells earlier in the disease may present some benefits on innate immune function. Finally, 
our data suggest that soluble MICA is a potential prognostic marker predictive of relapse in 
early stages. 
 
3.2. Material and Methods  
Human samples: Blood samples from healthy donors were purchased from the New York 
Blood Center. Blood samples from 175 untreated melanoma patients (stages I, II and III/IV) 
and plasma/sera from an additional cohort of 280 untreated melanoma patients (all stages) 
were obtained under the Interdisciplinary Melanoma Cooperative Group IRB approved 
protocols (#H10362). Patient demographics and primary tumor pathological characteristics 
were obtained for each patient at the time of enrollment. Recurrence and survival information 
were prospectively obtained via active follow-up every six months for all patients. The study 
was approved by the IRB at NYU in accord with a Federalwide Assurance approved by the 
Department of Health and Human Services, and all patients provided informed written 
consent at the time of enrollment. 
Reagents, cell lines, and methods used for NK cell purification and stimulation, Cell 
Staining and flow cytometry analysis, cytotoxicity, IFN-γ  production and proliferation 
assays are refered in CHAPTER 2. 
MICA, HMGB1 and TGF-β  expression: enzyme-linked immunosorbent (ELISA) assays 
for MICA, HMGB1 and TGF-β were performed on patients’ plasma/sera with commercially 
available kits (R&D systems and antibodies-online, respectively).  
Statistical analyses: Separate analyses were performed for each experiment individually. We 
compared the continuous measurements among patients based on the baseline characteristics 
by two tailed t-test (for two groups) or ANOVA (three groups). The continuous measurements 
	  





among patients with different tumor stage levels were compared using ANOVA. We 
compared the baseline tumor characteristics among patients with different MICA levels by 
using the Chi-square test. We also compared the distributions of Day.to.Recurrence and 
Day.to.Death survival among patients with different MICA levels with the Kaplan-Meier 
curves and log-rank test. We further evaluated the association between the MICA levels and 
Day.to.Recurrence, Day.to.Death, and Day.to.Death given recurrence survival by using the 
simple Cox regression model. In addition, we also applied multivariate cox regression models 
to assess the independent association between MICA levels and survivals.  
 
3.3. Results 
We have previously shown that NK cells from advanced melanoma patients (Stage III and IV) 
display an exhausted phenotype. However, the phenotype of NK cells in different phases of 
tumor progression (Stage I-IV) and how it can be related with prognostic factors is unknown.  
We studied a prospectively-enrolled cohort of patients (exploratory cohort) presenting with 
stage I (n=56), stage II (n=21) and stages III/IV (n=23) melanoma; and of 25 healthy donors. 
NK cells were purified from the peripheral blood and were characterized acccording to the 
expression of activating (NKG2D) (Figure 3.1.A) and inhibitory (KIR3DL1, Tim-3) 
receptors (Figure 3.1.B and 3.1.C), function (cytotoxicity, IFN-γ production and 
proliferation) and the intracellular expression of the transcription factors (T-bet and Eomes) 

















Our data show that NK cells gradually develop a phenotypic and functional profile consistent 
with exhaustion, as the melanoma stage advances. The development of this exhaustion 
phenotype along the different stages is characterized by: 1) progressive increase in expression 
Figure 3.1. MD NK cells gradually develop a phenotypic profile of exhaustion. An exploratory cohort of 
100 patients, who presented with melanoma stage I (n=56), stage II (n=21) and stage III/IV (n=23), plus 25 
HD were studied using different criteria: expression of the activating receptor NKG2D (A); inhibitory 
receptors KIR3DL1 (B) and Tim-3 (C); and T-bet and Eomes transcription factor expression (D). All 










of inhibitory receptors, concomitant with a progressive decrease of activating receptors 
(Figure 3.1.A, 3.1.B and 3.1.C); 2) progressive decrease in expression of the transcription 
factors, T-bet and Eomes (Figure 3.1.D); 3) impaired cytotoxicity, IFN-γ production and 













We then evaluated the association between each NK parameter (expression of 
inhibitory/activating receptors, function and expression of transcription factors) with 
demographic and clinical parameters (age, gender, stage, thickness, mitotic index, ulceration, 
metastasis). Interestingly, the expression of inhibitory receptors (KIR3DL1 and Tim-3), two 
main functions of NK cells (cytotoxicity and IFN-γ production) and T-bet expression are 
associated with important prognostic factors, such as thickness and presence of metastases. 
Thicker melanomas (> 1mm) were found to be associated with a higher expression of Tim-3 
(p=0.040), lower cytotoxicity (p=0.027) and lower cytokine production ability (p=0.03). 
Moreover, local or distant metastases were found to be associated with a higher expression of 
Tim-3 (p=0.004) and KIR3DL1 (p=0.0009), and a lower cytotoxicity (p=0.0004) and lower 
T-bet expression (p=0.02). These results were confirmed in an independent validation cohort 
of 50 patients presenting with stage I (n=37), stage II (n=9) and stage III/IV (n=4) (Tables 
3.1, 3.2 and 3.3). 
 
Figure 3.2. MD NK cells gradually develop a functional profile of exhaustion. An exploratory cohort of 
100 patients, who presented with melanoma stage I (n=56), stage II (n=21) and stage III/IV (n=23), plus 25 
HD were studied according to: cytotoxicity (upper panel), IFN-γ+ production (middle panel) and 
proliferating (lower panel). Upper plots show a representatiive melanoma patient from each stage group. All 


























Age Groups   0.2231  0.1648  0.0796 
<= 45y 26 (26) 33.62 (8.790)  13.51 (10.20)  79.70 (21.20)  
46-70y 38 (38) 31.41 (7.356)  16.29 (12.59)  81.81 (18.45)  
>=71y 36 (36)  30.16 (7.283)  20.48 (17.60)  69.37 (25.62)  
Gender   0.5189  0.4541  0.4448 
Female 36 (36) 30.86 (7.410)  16.88 (15.18)  75.25 (24.86)  
Male 64 (64) 31.91 (7.993)  14.66 (11.24)  79.24 (17.80)  
Stage   0.0008*  0.0044*  0.0001* 
I 56 (56) 29.44 (6.372)  13.35 (10.93)  83.10 (13.21)  
II 21 (21) 32.72 (7.275)  16.01 (14.66)  68.37 (31.13)  
















Age Groups   0.0413  0.1648  0.5496 
<= 45y 26 (26) 23.90 (10.66)  7.675 (5.847)  40.68(24.56)  
46-70y 38 (38) 25.58 (14.75)  6.545 (3.931)  41.26(27.67)  
>=71y 36 (36)  18.39 (8.440)  6.572 (3.035)  48.23 (30.16)  
Gender   0.8042  0.4519  0.7710 
Female 36 (36) 22.40 (12.23)  6.594 (3.893)  44.06 (28.36)  
Male 64 (64) 23.06 (12.14)  7.284 (4.802)  42.35 (25.44)  
Stage   0.0018*  0.0016*  0.0223* 
I 56 (56) 25.31 (12.48)  6.459 (4.187)  35.35 (20.01)  
II 21 (21) 21.81 (7.153)  6.082 (3.617)  25.23 (18.56)  
III/IV 23 (23) 13.72 (8.603)  5.189 (2.824)  11.07 (9.332)  
 
 
Table 3.1. Higher expression of Tim-3 and KIR3DL1, and a lower cytotoxity, cytokine production, 
proliferation and T-bet expression are associated with more advanced melanoma stages. The 
association of NK cell phenotype (expression of inhibitory/activating receptors, function and expression of  
transcription factors) with demographic and clinical parameters (age, gender and stage) was evaluated in an 
























Thickness   0.0406*  0.0153  0.0005 
<= 1 mm 58 (66) 29.36 (5.297)  12.83 (10.58)  83.10 (13.21)  
>1 mm 30 (34) 32.24  (5.464)  19.30 (13.57)  64.91 (29.85)  
Mitotic 
Index 
  0.0176  0.5935  0.6164 
<1/mm2 43 (49) 29.05 (5.246)  14.46 (12.34)  77.75 (20.68)  
>=1/mm2 40 (45) 32.21 (5.914)  15.89 (12.02)  75.07 (24.33)  
Unclassified 5 (6)       
Ulceration   0.0277  0.9155  0.7915 
Absent 65 (74) 29.45 (5.721)  14.58 (11.07)  78.19 (19.14)  
Present 15 (17) 33.61 (5.843)  14.23 (13.96)  80.00 (27.25)  















Thickness   0.0266*  0.0295*  0.2602 
<= 1 mm 58 (66) 25.17 (12.28)  7.591 (4.584)  45.69 (27.71)  
>1 mm 30 (34) 19.44 (8.184)  5.531 (3.292)  39.00 (25.39)  
Mitotic 
Index 
  0.1701  0.6104  0.6579 
<1/mm2 43 (49) 25.45 (13.12)  7.214 (4.556)  43.77 (26.95)  
>=1/mm2 40 (45) 21.78 (10.94)  6.720 (4.230)  46.44(27.07)  
Unclassified 5 (6)       
Ulceration2   0.9341  0.2820  0.5553 
Absent 65 (74) 23.77 (12.26)  7.020 (4.620)  43.57 (27.20)  
Present 15 (17) 23.45 (12.62)  5.586 (3.670)  38.87 (24.20)  
Unclassified 8 (9)       
 
Table 3.2. Higher expression of Tim-3 and a lower cytotoxity and cytokine production ability are 
associated with thicker melanomas. The association of NK cell phenotype (expression of 
inhibitory/activating receptors, function and expression of transcription factors) with demographic and 
clinical parameters (thickness, mitotic index and ulceration) was evaluated in an exploratory cohort of 100 















(MFI)      
Mean (SD) 
p-value KIR3DL1+ 
cells (%)  
Mean (SD) 
p-value T-bet+ cells 
(%)            
Mean (SD) 
p-value 
Metastasis   0.0042*  0.0009*  0.0157* 
Absent 77 (77) 30.33 (6.744)  14.06 (11.99)  79.38 (19.88)  














Metastasis   0.0004*  0.0625  0.0904 
Absent 26 (26) 24.83 (11.91)  7.243 (4.402)  45.39 (27.52)  
Present 38 (38) 13.72 (8.603)  5.189 (2.824)  31.62 (21.71)  
 
In addition we investigated whether there was any correlation between the expression of the 
inhibitory/activating receptors and NK cell function. Although some statistically significant 
correlations (p<0.05) were found, namely between Tim-3 and KIR3DL1 or NKp46 and 
cytotoxicity, the correlation coefficient was low (r2<0.3). 
These data demonstrate that NK cells become progressively exhausted in the context of 
melanoma progression. Moreover, the exhausted NK cell phenotype was found to be 
associated with clinical parameters such as thickness and metastases, well-known prognostic 
factors in melanoma. 
We next measured the expression of TGF-β (cytokine), MICA (NKG2DL) and HMGB1 
(Tim-3 ligand) in the plasma of melanoma patients from the same exploratory and validation 
cohort as described in Figure 3.2 using an ELISA kit. MICA (n=111) and HMGB1 (n=61) 
expression was found to increase from stage I to stage IV (p=0.02 and p=0.045, respectively) 
(Figures 3.3.A and 3.3.B). TGF-β (n=65) levels increased from stage II to stage III/IV, 
however this increase is not statistically significant (Figure 3.3.C). In addition we 
investigated whether there was any correlation between the expression of MICA, HMGB1 or 
Table 3.3. Higher expression of Tim-3 and KIR3DL1, lower cytotoxity and lower T-bet expression are 
associated with local or distant metastases. The association of NK phenotype (expression of 
inhibitory/activating receptors, function and expression of transcription factors) with the presence of 
regional/distant metastases was evaluated in an exploratory cohort of 100 patients and validated in an 









TGF-β and NK cell phenotype (receptors expression and function), however no statistically 
significant association was found. 
 
 
We then studied the expression of MICA and HMGB1 in an independent validation cohort 
(n=280). We divided the cohort in three groups, according to MICA expression: 1) level 1, no 
MICA expression (n=106); 2) level 2, <500pg/mL (n=129) and 3) level 3, >= 500pg/mL 
(n=45) (Table 3.4). Of note, higher levels of sMICA in the plasma of melanoma patients are 
associated with thicker melanomas, advanced stages, higher recurrence and death rate. 
Interestingly, we observed that higher expression of MICA in the plasma was associated with 
shorter recurrence-free survival (p=0.0058) (Figure 3.4.A), with a hazard ratio for recurrence 
of 2.4 between level 1 and level 3 of MICA expression (p=0.002) (Table 3.5). Remarkably, 
we also observed an association between higher MICA expression and shorter overall survival 
(p=0.0056) (Figure 3.4.B), with a hazard ratio for death of 2.6 between levels 1 and 3 (Table 
3.5). We did not observe any association between HMGB1 expression and prognosis.  
Figure 3.3. MICA and HMGB1 expression in the plasma/serum from melanoma patients increases 
from stage I to stage IV. Expression of (A) MICA, (B) HMGB1, (C) TGF-β in the plasma of melanoma 
patients at different stages of the disease (by ELISA). All experiments were performed in duplicate. 
	  
	  






Level=1   Level=2   Level=3     
106 37.9% 130 46.4% 44 15.7%   
values percent values percent values percent   
Gender 
F 53 50.0% 52 40.0% 17 38.6% 
0.236 M 53 50.0% 78 60.0% 27 61.4% 
NA 0   0   0   
Age at Diagnosis 
median 63.0    65.0    64.5    
0.867 
mean 62.1  (16.7) 61.8  (17.2) 63.4  (16.2) 
Histologic.subtype 
NM 50.0  0.5  45.0  0.4  21.0  0.5  
0.213 
SSM 33 32.7% 53 44.5% 12 27.9% 
OTHER 18 17.8% 21 17.6% 10 23.3% 
NA 5   11   1   
Thickness 
median 2.4    2.0    2.1    
0.012 
mean 3.7  (4.7) 2.4  (2.1) 3.2  (3.0) 
Mitoses 
NONE 16 15.8% 29 24.6% 9 20.9% 
0.281 PRESENT 85 84.2% 89 75.4% 34 79.1% 
NA 5   12   1   
Ulceration 
ABSENT 58 55.8% 84 68.3% 24 54.5% 
0.094 PRESENT 46 44.2% 39 31.7% 20 45.5% 
NA 2   7   0   
TILs 
ABSENT 32 33.0% 23 20.4% 7 17.5% 
0.054 PRESENT 65 67.0% 90 79.6% 33 82.5% 
NA 9   17   4   
Stage.and.substage 
I 17 16.0% 48 36.9% 14 31.8% 
0.000 
II 80 75.5% 49 37.7% 16 36.4% 
III 8 7.5% 27 20.8% 14 31.8% 
IV 1 0.9% 6 4.6% 0 0.0% 
NA 0   0   0   
Recurrence 
No 83 79.0% 86 69.4% 21 47.7% 
0.001 Yes 22 21.0% 38 30.6% 23 52.3% 
NA 1   6   0   
Outcome_index 
0 86 81.1% 92 70.8% 23 52.3% 
0.002 1 20 18.9% 38 29.2% 21 47.7% 
NA 0   0   0   
 
 
Table 3.4. Higher levels of sMICA in the plasma of melanoma patients are associated with thicker 
melanomas, advanced stages, higher recurrence and death rate. Demographic (gender and age) and 
tumor (histologic subtype, thickness, mitosis, ulceration, TILs, stage) characterístics, and outcomes 
(recurrence and death), for different melanoma patient groups defined according to plasma sMICA levels 
(level 1, no expression; level 2, <500pg/mL; level 3, >= 500pg/mL). All experiments were performed in 









 Baseline Level Coeff HR p-value <.1*,<.05** 
Day.to.Recurrence 
Level=1 Level=2 0.31 1.363 0.209   
Level=1 Level=3 0.885 2.423 0.002 ** 
Day.to.Death 
Level=1 Level=2 0.364 1.439 0.189   
Level=1 Level=3 0.968 2.632 0.002 ** 
Day.to.Death Given Recurrence 
Level=1 Level=2 0.683 1.98 0.061 * 







Table 3.5. Higher levels of sMICA in the plasma of melanoma patients are associated with shorter 
recurrence free survival and overall survival. Recurrence free survival and overall survival for different 
melanoma patient groups defined according to plasma sMICA levels (level 1, no expression; level 2, 
<500pg/mL; level 3, >= 500pg/mL). All experiments were performed in duplicate. 
 
	  
Figure 3.4. Higher levels of sMICA in the plasma of melanoma patients are associated with shorter 
recurrence free survival and overall survival. (A) Recurrence free survival and (B) overall survival for 
different melanoma patient groups defined according to plasma sMICA levels (level 1, no expression; level 










AJCC staging is the best prognostic classification in melanoma thus far. However, if we look 
at the 5 year overall survival at stage II (primary melanoma lesion with thickness > 1mm, 
without lymph node or distant metastases) for instance, this ranges from 50-90%, which is 
still considered too broad17. Therefore, new prognostic markers are needed to improve the 
prognostic classification. We hypothesized that MICA expression in the plasma/serum may 
function as a prognostic factor, independent of AJCC staging. Our results show that higher 
levels of MICA in the plasma are associated with shorter recurrence-free survival (HR=1.8; 
p=0.046) and shorter overall survival (HR=2.5; p=0.005), even after adjustment for some 
potencial confounders, including age and staging (Table 3.6).  
 
Response Baseline Level Coeff HR p-value <.1*,<.05** 
Day.to.Recurrence 
Level=1 Level=2 0.042 1.043 0.871   
Level=1 Level=3 0.604 1.829 0.046 ** 
Age Age 0.013 1.013 0.067 * 
Stage=I Stage=II 0.19 1.209 0.533   
Stage=I Stage=III 1.385 3.994 0 ** 
Stage=I Stage=IV 2.056 7.817 0 ** 
Gender=F Gender=M 0.376 1.456 0.086 * 
Day.to.Death 
Level=1 Level=2 0.258 1.294 0.365   
Level=1 Level=3 0.905 2.471 0.005 ** 
Age Age 0.035 1.035 0 ** 
Stage=I Stage=II 0.613 1.846 0.075 * 
Stage=I Stage=III 1.458 4.296 0 ** 
Stage=I Stage=IV 2.39 10.919 0 ** 
Gender=F Gender=M 0.238 1.268 0.316   
Day.to.Death Given Recurrence 
Level=1 Level=2 0.557 1.746 0.139   
Level=1 Level=3 0.826 2.284 0.042 ** 
Age Age 0.013 1.013 0.172   
Stage=I Stage=II 0.542 1.719 0.191   
Stage=I Stage=III 1.023 2.781 0.013 ** 
Stage=I Stage=IV 1.553 4.725 0.007 ** 
Gender=F Gender=M 0.069 1.071 0.814   
 
Table 3.6. Higher levels of sMICA in the plasma of melanoma patients are associated with shorter 
recurrence free survival and overall survival, adjusting for age, gender and stage. Recurrence free 
survival and overall survival for different melanoma patient groups defined according to plasma sMICA 
levels (level 1, no expression; level 2, <500pg/mL; level 3, >= 500pg/mL), adjusted for age and stage. All 
experiments were performed in duplicate. 
	  
	  





Taken together, our data suggest that sMICA is a potential prognostic factor and a potential 
biomarker predictive of recurrence. 
 
3.4. Discussion 
Our data suggest that NK cells become exhausted in the context of melanoma, making them 
an interesting population to target therapeutically. Moreover, as the exhaustion phenotype is 
acquired progressively through the stages, it may be possible to intervene early in the course 
of tumor progression.  
NK cells, together with T cells, are the most efficacious anti-tumor cell types. However, the 
downregulation of HLA class I in melanoma cells might play a significant role in the 
pathogenesis and clinical course of the disease, and it represents a considerable problem for T 
cell-based immunotherapy. On the contrary, NK cells preferentially target tumor cells with 
low HLA class I expression, through IFN-γ production and direct cytotoxicity, making them a 
potential and interesting therapeutic option. Furthermore, NK cells have the ability to 
recognize and lyse a broad range of tumor cells without prior priming180. Three sets of 
immunotherapeutic NK-cell based strategies have been studied thus far. Firstly, cytokines that 
boost the NK cell response, such as IL-2, IL-21 or IL-15. In early experiments, NK cells were 
activated by IL-2 ex vivo and adoptively transfered to the patients (called LAK therapy) with 
advanced metastatic renal cancer and melanoma181. Therefore, NK cell activity can be 
boosted in melanoma patients treated with high doses of IL-2, although IL-2 alone has yielded 
limited beneficial effects and is associated with considerable side effects182. Secondly, NK 
cells are an attractive alternative, or potential adjuvant, to T cell-based ACT in the context of 
MHC-I-deficient tumor cells170. Thirdly, inhibitory receptor blockade or the crosslinking of 
activating receptors. The blockade of inhibitory receptors, such as anti-KIRs, promotes tumor 
rejection in preclinical models of leukemia and melanoma. Phase I trials are currently 
investigating the effects of a fully human IgG4 mAb that blocks the interaction between 
KIR2DL1,2,3 inhibitory receptors and HLA-C ligands in patients with AML and multiple 
myeloma, in remission, after chemotherapy183. In addition to the activating and inhibitory 
receptors, NK cells express several members of the signalling lymphocyte activation molecule 
(SLAM/CD150) family that play an important role in the regulation of NK cell function. 2B4 
and CS1 (CD319, CRACC) are two members of the SLAM family that promises targeting 
	  





NK mediated cytolytic function against tumor cells184,185,186 Another important point to be 
taken into account is the potential of NK cells to execute antibody-dependent cellular 
cytotoxicity through the CD16 (FCRγIII) receptor on their surface. It has been shown that 
treatment with monoclonal antibodies like rituximab (anti-CD20), cetuximab (anti-EGFR) 
and trastuzumab (anti-HER2)187 can trigger effector functions of NK cells against tumor 
targets.  
Our results demonstrate that NK cell exhaustion is a progressive phenomena that follows 
tumor progression. The exact mechanism underlying this process is still unclear; however it is 
possible that NK cells become exhausted due to systemic production of cytokines or within 
the TME in response to specific inhibitory molecules, or due to contact with 
immunossuppressive cells (regulatory T cells, tumor associated macrophages and myeloid 
derived suppressor cells). In fact, chronic stimulation with the activating cytokines IL-2 and 
IL-15 has been previously shown to induce NK cell exhaustion175,176. Moreover, molecules 
such as TGF-β, IL-10 and IDO, were shown to inhibit NK cells’ function165. Furthermore, 
under certain conditions, such as hypoxia, MICA is shed from tumor cells by 
metalloproteases. Sera of patients with epithelial and hematopoetic malignancies contain 
elevated levels of sMICA. Soluble MICA has been shown to systemically downregulate 
NKG2D and inhibit NK cells’ cytotoxicity157. Moreover, reduced NKG2D expression, and 
consequent impaired cytotoxicity on tumor-infiltrating and peripheral blood T and NK cells of 
tumor patients correlates with elevated sMICA levels in the sera157.  
It is important to point out that many tumor cells, including those in the lung, breast, kidney 
and colon, express different NKG2DL on their membrane, and that, higher expression of 
MICA is associated with a good prognosis188. As mentioned before, MICA has an opposite 
role depending on whether it is expressed on the membrane of the tumor cells, activating the 
immune system, or in the plasma, inhibiting it. In this study we have shown that levels of 
MICA in the plasma/serum are higher in advanced melanoma patients when compared with 
early stages. Moreover, we have observed, in an independent validation cohort, that higher 
levels of MICA are associated with a shorter median survival in the context of melanoma.  
The AJCC staging system is the best and most commonly used prognostic classification 
system. It stratifies solid tumors according to prognosis based on size of the tumor and 
presence/absence of lymph node/distant metastases. Nevertheless, the range of 5 year overall 
	  





survival is still too broad in some stages, mainly stage II (50-90%). MICA, whose levels can 
be easily measured in the plasma/serum of melanoma patients by ELISA, is a potential 
prognostic marker. However, its quantitation needs to be standardized and validated in 
different cohorts of patients from different centers. In addition, we did not see any correlation 
between the NKG2D levels in the membrane of NK cells and MICA expression in the plasma 
of the same patients. This result can be explained by the fact that plasma from the patients 
contains factors that can regulate NKG2D expression independently of MICA expression189. 
In fact, TGF-β has also been shown to decrease the transcription of MICA, UL16 binding 
protein 2 (ULBP2), and UL16 binding protein 4 (ULBP4) in human gliomas190. Moreover, the 
presence of TGF-β can also downregulate NKG2D receptor expression on effector cells, and 
blocking TGF-β can lead to an increased expression of NKG2D regardless of sMICA present 
in the serum191. 
In conclusion, this study suggests that NK cells from melanoma patients acquire an exhausted 
phenotype as they advance in stage. Moreover, higher expression of inhibitory receptors and 
impaired function are associated with well-known worse prognostic parameters (melanomas 
that are thicker than 1 mm and the presence of metastasis). Interestingly, higher levels of 
MICA in the plasma, that may be involved in the mechanism of NK cell exhaustion, are 















CHAPTER 4:  
REVERSAL OF NK CELL EXHAUSTION IN ADVANCED 
MELANOMA BY TIM-3 BLOCKADE 
 
4.1. Introduction 
Immune checkpoints play a key role in the maintenance of immune tolerance, avoiding 
autoimmune reactions. However, they are also responsible for an innefficient anti-tumor 
response, leading to tumor progression. Tim-3, together with CTLA-4 and PD-1, among 
others, belong to this family of immune checkpoints45. 
Tim-3 plays a crucial role in mediating T cell exhaustion in both viral infections and 
tumors119,121,124 , and its blockade reverses the exhausted phenotype of CD4+ and CD8+ T cells 
in several chronic diseases including melanoma93,123,192. Whereas in resting T cells Tim-3 is 
minimally expressed and upregulated only after chronic stimulation, it is constitutively 
expressed at considerably higher levels in activated NK cells132. Recent publications, 
however, have reported conflicting data regarding Tim-3 function in NK cells132,133. Ndhlovu 
and colleagues showed that Tim-3 inhibits NK cell-mediated cytotoxicity132 while another 
study suggested that Tim-3 may instead enhance IFN-γ production133. Both studies only 
evaluated healthy donors and not patients with chronic diseases such as cancer, where Tim-3 
expression on NK cells may have a more significant immunomodulatory role.  
In this study, we aimed to study the Tim-3 function in NK cells from advanced melanoma 
patients. We found that Tim-3 is an inhibitory receptor in NK cells from advanced melanoma 
patients, and that is upregulated on functionally impaired/exhausted NK cells. Most 
importantly, we showed that Tim-3 blockade reversed this NK cell exhausted phenotype. 
These data open exciting avenues for new therapies targeting Tim-3 in tumor immunotherapy. 
 
	  





4.2. Material and Methods 
Human samples: Blood samples from healthy donors were purchased from the New York 
Blood Center. Blood samples were obtained under the Interdisciplinary Melanoma 
Cooperative Group IRB approved protocols (#H10362) from 45 untreated melanoma patients 
(stages I, II and III/IV). The study was approved by the Institutional Research Board at NYU 
in accord with a Federalwide Assurance approved by the Department of Health and Human 
Services, with all patients providing informed written consent at the time of enrollment. 
Reagents: For blocking experiments - 10 or 20µg/ml of Tim-3 blocking antibody (Biolegend, 
clone 2E2; R&D #AF2365), galectin-9 blocking antibody (BioLegend), or IL-2R (α, β and γ 
chains – R&D Biosystems) blocking antibody was added to the culture 1 hour before 
initiating the functional assays. For crosslinking experiments - the same anti-Tim-3 antibody 
(Biolegend) was used. Anti-CD16 and anti-CD94 antibodies from Biolegend were also used 
to coat beads and in the reverse-antibody-dependent cell-mediated cytotoxicity (ADCC) 
assay. For both experiments, crosslinking and blocking, we used the IgG1 isotype control 
from BD. 7-aminoactinomycin D (7AAD), purchased from Biolegend, was used. For 
stimulation - rh-Gal-9, purchased from R&D systems, was added to NK cells 1h before the 
cytotoxic assay. Reagents for the staining assay were described in CHAPTER 1. 
Cell lines: Gmel, FM29, WM1552, WM3248, WM793b are melanoma cell lines used as 
target cell in cytotoxic assays in diferent experiments. Gmel and FM29 cells were cultured in 
complete media (RPMI-1640 - Life Technologies) supplemented with 10% FBS, 2mM L-
glutamine, 100U/ml penicillin, and 100µg/ml streptomycin. Gmel is a melanoma cell line that 
expresses galectin-9 intracellularly and with 5% of these cells expressing galectin-9 on the 
membrane. Melanoma cell lines WM1552, WM3248, WM793b were purchased from the 
Wistar Institute. The P815 cell line was purchased from ATCC. This cell line is FcR+ and was 
used for the reverse ADCC-assay. The K562 cell line was described in CHAPTER 2. 
NK cell purification and stimulation, cell Staining and flow cytometry analysis, 
Cytotoxicity, IFN-γ  production and proliferation assays were described in CHAPTER 2. 
Blocking experiment: 10 or 20µg/ml of Tim-3 blocking antibodies (Biolegend, clone 2E2 or 
R&D #AF2365) was added to the NK cell culture 1 hour before initiating the functional 
assays (i.e. before adding K562 cells in the cytotoxicity assay, IL-12 in the cytokine 
	  





production assay and IL-2 in the proliferation assay). An IgG1 antibody from BD Biosciences 
was used as isotype control.   
Cell sorting: Gmel cells were first stained for Gal-9, following the protocol described above. 
These cells were then sorted as Gal-9--Gmel and Gal-9+-Gmel by flow cytometry. The same 
steps were followed to sort NK cells into Tim-3+ and Tim-3- NK cells. 
Crosslinking experiment: (A) Coated–Beads: Dynabeads® Pan Mouse IgG (Invitrogen) 
were labeled with purified mouse IgG1, κ isotype control (BD Biosciences) or purified human 
anti-Tim-3 (Biolegend) according to the manufacturer’s instructions. Antibody labeled beads 
were added to the NK cell suspension at a 1:1 ratio for 30 min at 40C, then incubated at 370C 
for 90 min. The functional assays were then performed as previously described. (B) Reverse-
ADCC: NK cells were co-cultured with Fc receptor+ (FcR+) P815 cells and different 
antibodies were added to the reaction: anti-Tim-3, anti-CD94 (negative control) or anti-CD16 
(positive control) antibody. 
Endocytosis: To assess whether Tim-3 was endocytosed after Tim-3 blockade, IL-2-
stimulated NK cells from healthy donors were incubated with the Tim-3 blocking mAb or 
IgG1 isotype control, as previously described, for 15 min, 30 min and 1 hour. Cells were then 
fixed, permeabilized or not, and stained with a Phycoerythrin (PE)-conjugated anti-mouse 
mAb in order to detect Tim-3 blocking antibody on the cell surface and/or in the cytoplasm. 
Statistical analyses: Separate analyses were performed for each experiment individually. 
Two tailed t tests were used. Analyses took into account paired observations within donors 
when appropriate, or unpaired observations when we comparing parameters between healthy 
and melanoma NK cells.  
 
4.3. Results 
Tim-3 is upregulated in NK cells from advanced melanoma patients; however the role of this 
receptor in this context remains unknown. In order to determine the role of Tim-3 in NK cell 
exhaustion, we developed a system to engage Tim-3 through crosslinking, by using anti-Tim-
3 antibody-coated beads. We observed that Tim-3 activation in MD NK cells reduced 
cytotoxicity by approximately 20% (p=0.0361) (Figure 4.1.A) and IFN-γ production by 25% 
	  





(p=0.0176) (Figure 4.1.B), as compared to controls (IgG coated beads). Moreover, we 
performed a reverse-ADCC assay using FcR+ P815 cells that bind the Fc portion of 
antibodies, thus allowing antibodies to crosslink their relevant target ligands on other cells. 
We co-cultured NK cells from melanoma donors with P815 cells and added the following 
antibodies to the co-culture: anti-Tim-3, anti-CD94 (negative control) or anti-CD16 (positive 
control). As expected, CD16 crosslinking activated NK cells rendering them more cytotoxic, 
while CD94 crosslinking reduced NK cell cytotoxicity. As shown below, when Tim-3 was 





Figure 4.1. Tim-3 engagement inhibits NK cell functions. (A) The percentage of LAMP-1
+
 (n=8) and (B) 
the MFI of IFN-γ
+
 cells (n=6), of melanoma donors' NK cells pre-incubated with IgG-coated beads or anti-
Tim-3 antibody-coated beads for 2 hours prior to evaluating cytotoxic function or IFN-γ production. (C) 
Reverse-ADCC assay using FcR
+
 P815 cells. NK cells from melanoma donors were co-cultured with P815 
cells and different antibodies were added to the reaction: anti-Tim-3, anti-CD94 (negative control) or anti-
CD16 (positive control) antibodies. Data were normalized to values obtained for the condition without any 
antibody: (A and B) with IgG-coated beads (100%); (C) with no antibody. All experiments were performed 









We used the same two systems to crosslink Tim-3 on HD NK cells, anti-Tim-3 antibody-
coated beads (Figure 4.2.A) and the reverse-ADCC (Figure 4.2.B), as well as, anti-Tim-3-
coated K562 cells (Figure 4.2.C). Our study showed that Lamp-1 expression was inhibited by 
NK cells (first two systems), and that there was a decrease in K562 cell apoptosis (third 
system). This finding confirms that Tim-3 acts as an inhibitory receptor in NK cells and that 
upon binding it downmodulates NK cell function in the context of advanced melanoma. It is 
important to point out that, as NK cells from melanoma patients may have already undergone 
significant Tim-3-mediated inhibition in vivo, it is not surprising that Tim-3 binding did not 
result in greater inhibition of NK cell function. In HD, Tim-3 binding also resulted in a 
significant decrease of cytotoxicity as previously described132. Tim-3 also acts as an 
inhibitory receptor on T cells, that when chronically activated, induces T cell apoptosis. 
























Figure 4.2. Tim-3 engagement on NK cells from healthy donors inhibits their cytotoxicity. (A) 
Graphs represent the percentage (left  panel) and the MFI (right  panel) of LAMP-1
+
 healthy donors' 
NK cells incubated with IgG-coated beads or anti-Tim-3 antibody-coated beads 2 hours previous to 
performing the cytotoxicity assay (n=16). Data were normalized to values obtained for the condition 
with IgG-coated beads. (B) Reverse-ADCC assay. Graph represents the % of LAMP-1
+
 healthy donors' 
NK cells co-cultured with P815 cells, in the presence of anti-Tim-3, anti-CD94 or anti-CD16 antibodies 
for 4 hours (n=5). (C) K562 cells were stained with CFSE, coated with IgG or anti-Tim-3, and co-
cultured with NK cells from healthy donors for 4 hours (n=6). Data were normalized to values obtained 




 K562 cells (“killed cells”) 
following a killing assay with NK cells from healthy donors is shown. (D) We performed a viability 
assay using the reverse-ADCC assay. MD NK cells were co-cultured with P815 cells, and anti-Tim-3, 
anti-CD94 or anti-CD16 antibodies were added to the reaction for 4 hours (n=5). The graph shows the 




 NK cells (live NK cells) for each condition. All experiments were 
performed in duplicate. 
	  





Gal-9 is the most well-studied Tim-3 ligand identified thus far. For this reason we chose to 
use recombinant and surface-bound Gal-9 as Tim-3 agonists. NK cells from HD were 
incubated with 25 and 50nM of rh-Gal-9 1 hour before assessing cytotoxicity, and displayed a 
significant decrease in Lamp-1 expression, but without significant toxicity (Figure 4.3.A). 
We next were able to abrogate this effect by blocking Gal-9 with a specifc blocking antibody 
or β-lactose (Figure 4.3.B). We then used a more physiological approach by using the 
melanoma cell line Gmel as source of Gal-9. Gmel cells were sorted according to their surface 
expression of Gal-9 into Gal-9+-Gmel and Gal-9--Gmel cells and were then used as target 
cells. We found that NK cell-mediated cytotoxicity from both HD or MD was lower in the 
presence of Gal-9+-Gmel cells compared with Gal-9--Gmel cells (Figure 4.3.C). We then 
sorted NK cells according to Tim-3 expression into Tim-3+ vs Tim-3- NK cells, and repeated 
the same experiment. The suppressive effect of Gal-9 was only evident in the presence of 
Tim-3+ NK cells (Figure 4.3.D). 
	  



























Figure 4.3. Tim-3 engagement by Galectin-9 on NK cells from healthy donors and melanoma patients 
inhibits their cytotoxicity. (A) Expression of LAMP-1 (MFI, n=20) by healthy donors' NK cells incubated 
with 25 or 50nM/ml of soluble rh-Gal-9 1 hour before assessing cytotoxicity (left panel) and NK cells’ 
viability (right panel) using K562 cells as targets. (B) Lamp-1 expression (MFI) by healthy donors' NK 
cells (n=6) incubated with 50nM/ml of soluble rh-Gal-9 alone or in the presence of anti-Gal-9 antibody 
(10µg/mL) or β-lactose (50nM), to block the effect of soluble rh-Gal-9. (C) We used another approach to 









Gmel. Graphs represent the expression of 





Gmel as target cells. Data were normalized to values obtained for the condition 
without rh-Gal-9 (Figure 4.A and 4.B) or for the condition with Gal-9
-
-Gmel cells as target cells (Figure. 









-Gmel as target cells.  
	  





In T cells, Tim-3 has been described as a marker of T cell exhaustion that, when blocked, can 
reverse the function of these cells93,115,123. In order to study whether Tim-3 blockade could 
also reverse the function of MD NK cells, we blocked the Tim-3 receptor by adding a soluble 
Tim-3 blocking antibody (10 and 20µg/mL; clone 2E2) 1 hour before assessing NK cell 
functions in various assays. Blocking Tim-3 significantly improved cytotoxicity by 20-25% 
(p=0.002) (Figure 4.4.A). We obtained the same results with a different Tim-3 blocking 
antibody (R&D #AF2365; Figure 4.4.B). Both blocking antibodies were validated in a killing 
assay (Figure 4.4.C). Interestingly, addition of Galectin-9-blocking antibody did not affect 
cytotoxicity, suggesting that other Tim-3 natural ligands may participate instead, since K562 
cells do not express galectin-9 (Figure 4.4.D). Importantly, Tim-3 blockade improved NK 
cell cytotoxicity against four different melanoma cell lines (Figure 4.4.E). All of the four 
melanoma cell lines express galectin-9 (Figure 4.4.F), however the expression levels did not 
































Figure 4.4. NK cell exhaustion can be reversed by Tim-3 blockade - Cytotoxicity. (A) Graph 
representing the expression of LAMP-1 (n=15; MFI) in melanoma donors' NK cells incubated with 10 or 
20µg/ml of soluble Tim-3 blocking antibody 1 hour before the cytotoxic assay. (B) The plot shows the 
percentage of melanoma donors' Lamp-1+ NK cell subset (n=8) incubated with 10µg/ml of a different 
soluble Tim-3 blocking antibody (R&D #AF2365) or IgG isotype control 1 hour before the cytotoxic assay. 
(C) Plot shows the percentage of CFSE+7AAD+ K562 cells (% of killed K562 cells) in the presence of 
10µg/ml of two different Tim-3 blocking antibodies (clone 2E2 or R&D #AF2365) 1h before the killing 
assay (n=9 MD). (D) To determine if Galectin-9 was involved in our system, we used a blocking antibody 
for Galectin-9 for 1h (10 and 20ug/ml) and assessed cytotoxicity in NK cells from healthy donors (n=6) 
against K562 cells. Graphs represent percentage of Lamp-1+ cells (left panel) and MFI (middle panel) of 
Lamp-1+ cells. (Right panel) The plot shows galectin-9 expression in K562 cells. (E) Graphs depict the 
percentage of lamp-1+ NK cells (n=5) incubated with 10µg/ml of soluble Tim-3 blocking antibody 1h before 
the cytotoxicity assay using melanoma cell lines as target cells: WM1552 (upper panel); WM793b, 
WM3248 or FM29 (lower panel). (F) The graphs show galectin-9 expression in the melanoma cell lines: 
FM29, WM793, WM1552 and WM3248. Data were normalized to values obtained for each condition 
without blocking antibody. All experiments were performed in duplicate. 
 
	  





IFN-γ production also increased in the presence of Tim-3 blocking antibody by 15-20% 










Figure 4.5. NK cell exhaustion can be reversed by Tim-3 blockade – IFN-γ production. (A) Graph 
represents the percentage of IFN-γ
+
 cells (n=12) in melanoma donors' NK cells incubated with 10 or 
20µg/ml of soluble Tim-3 blocking antibody 1 hour before the functional assay. Plots depicting the 
percentage of IFN-γ
+
 with (right panel) and without (middle panel) Tim-3 blockade, from a representative 
melanoma patient. (B) The plot shows the percentage of melanoma donors' IFN-γ
+
 NK cells subset (n=8) 
incubated with 10µg/ml of a different soluble Tim-3 blocking antibody (R&D #AF2365) or IgG isotype 
control 1h before performing the IFN-γ production assay. Data were normalized to values obtained for each 
condition without blocking antibody. All experiments were performed in duplicate. 
	  





Finally, the percentage of proliferating cells dramatically increased by 30% and 60% with the 
addition of 10 and 20µg/mL anti-Tim-3 antibody (p=0.009) (Figures 4.6.A and 4.6.B). The 
isotype control did not produce any effect on NK cell cytotoxicity, IFN-γ production or 




Figure 4.6. NK cell exhaustion can be reversed by Tim-3 blockade – proliferation. (A) Graph 
represents the percentage of proliferating cells (n=10; %) in melanoma donors’ NK cells incubated with 10 
or 20µg/ml of soluble Tim-3 blocking antibody 1 hour before performing the functional assay. Plots 
depicting the percentage of proliferating cells with (right panel) and without (middle panel) Tim-3 
blockade from a representative melanoma patient. (B) Plot showing the percentage of proliferating NK cells 
from melanoma donors (n=8) incubated with 10µg/ml of a different soluble Tim-3 blocking antibody (R&D 
#AF2365) or IgG isotype control 1 hour before the proliferation assay was performed. (C) Graphs represent 
the expression of LAMP-1 (n=5; left panel), IFN-γ (n=5; middle panel) and the percentage of proliferating 
cells (n=5; right panel) in NK cells from melanoma donors incubated with 10 µg/ml of soluble Tim-3 
blocking antibody (clone 2E2) or IgG1 isotype control 1 hour before the functional assays. Data were 
normalized to values obtained for the condition without blocking antibody. All experiments were performed 
in duplicate. 
	  





We next investigated the mechanism underlying the reversal of NK cell exhaustion by 
blockade of Tim-3. NK cells treated with Tim-3 blocking antibody showed a clear decrease of 
surface membrane Tim-3 levels (Figure 4.7.A). We hypothesized that Tim-3 expression at 
the surface membrane decreased due to internalization. To address this possibility, NK cells 
from HD were first incubated with Tim-3 blocking antibody or isotype control, then fixed, 
permeabilized and stained with a PE anti-mouse IgG antibody in order to detect Tim-3 
antibody, both on the cell surface and in the cytoplasm. As control, we also assessed antibody 
levels in cells that were fixed but not permeabilized. These experiments demonstrated that 
soluble Tim-3 blocking antibody induced internalization of Tim-3 (Figures 4.7.B and 4.7.C). 
To demonstrate that reduced Tim-3 levels on the membrane account for reversal of NK cell 
exhaustion, NK cells were pre-treated with soluble Tim-3 blocking antibody and residual 
Tim-3 was cross-linked using anti-Tim-3-coated beads. As expected, in this context, the beads 
had no effect on cytotoxicity, due to prior internalization of Tim-3 by the soluble blocking 
antibody (Figure 4.7.D). Moreover, we confirmed that this effect is indeed due to Tim-3 
blockade and not consequent to the engagement of the Fc portion of the Tim-3 blocking 
antibody with CD16 receptor (FcγRIII) in NK cells. Indeed, before adding the Tim-3 blocking 
antibody, we incubated MD NK cells with a CD16 (FcγRIII) blocking antibody for 1 hour. 
This anti-CD16 antibody prevents the possibility that the Fc portion of other antibodies added 
to the reaction (in this case Tim-3 blocking antibody) binds to CD16 receptor (FcγRIII). 
Figure 4.7.E shows an increase of cytotoxicity when using Tim-3 blocking antibody, even 

















Figure 4.7. Soluble Tim-3 blocking antibody induces internalization of Tim-3. (A) Plot depicting the 
decrease of Tim-3 expression in the membrane of NK cells after 1 hour treatment with soluble Tim-3 
blocking antibody. (B) Graph representing the MFI of NK cells positive for the PE anti-mouse IgG antibody, 
with or without permeabilization (n=6). (C) The previous experiment was repeated also including an IgG1 
isotype control. Graph showing the percentage of cells positive for the PE anti-mouse IgG antibody after 1 
hour of incubation with antibodies, soluble Tim-3 blocking antibody and IgG1 isotype control (n=6). (D) 
Graph representing the MFI of Lamp-1
+
 NK cells from healthy donors (n=6) after performing a cytotoxic 
assay with K562 cells. (Left panel) NK cells were pre-incubated (2 hours) with anti-Tim-3-coated beads or 
IgG-coated beads. (Right panel) Soluble Tim-3 blocking antibody was added 1 hour before crosslinking 
with anti-Tim-3-coated beads as described previously. Data were normalized to values obtained for the 
condition with beads alone. (E) The graph shows the percentage of Lamp-1+ NK cells after 1 hour treatment 
with 10µg/ml CD16 blocking antibody alone or after 1 hour treatment with 10µg/ml CD16 blocking 
antibody followed by 1h treatment with 10µg/ml soluble Tim-3 blocking antibody. All experiments were 
performed in duplicate. 
	  





Levels of activating and inhibitory receptors on the membrane of NK cells treated with Tim-3 
blocking antibody were also measured. Interestingly, CD16 expression increased by 10% 
after Tim-3 blockade (Figure 4.8.A). Likewise, there was a significant increase in expression 
of α and γ chains of the IL-2R (Figure 4.8.B). NK cells respond to IL-2 stimulation with 
increased expression of activating and inhibitory receptors, cytotoxicity and IFN-γ production. 
In order to define the role of each chain of IL-2R in the NK cell response, we cultured 
purified NK cells from HD with 200UL/mL of IL-2 and separately blocked each chain of the 
IL-2R (α, β and γ). After two days, expression of activating and inhibitory receptors, and 
cytotoxicity were assessed. Our data demonstrate that both the α chain and mainly the γ chain 
play a key role in the expression of activating and inhibitory receptors (Figure 4.8.C), and in 
enhancing NK cell-mediated cytotoxicity after IL-2 stimulation (Figure 4.8.D).  
	  








Figure 4.8. Soluble Tim-3 blocking antibody upregulates IL-2R, rendering them more responsive to 
IL-2 stimulation. (A) Plot showing the expression of CD16 receptor (MFI) in NK cells untreated or after 1 
hour treatment with 10µg/ml of soluble Tim-3 blocking antibody. (B) Plots showing the expression of IL-
2R α and γ chains (% of positive cells) in NK cells untreated or after 1 hour of treatment with 10µg/ml of 
soluble Tim-3 blocking antibody (n=7). (C) Graphs depict the NK cell expression of KIR3DL1 (left panel - 
MFI) and NKG2D (right panel - % NKG2D+ cells) after two days of culture with 200U/mL untreated or 
treated with anti-α chain, anti-β chain or anti-γ chain blocking antibodies. (D) Graph depicting the 
percentage of Lamp-1
+
 NK cells after two days of culture with 200U/mL of IL-2, untreated or treated with 
blocking antibody for α, β or γ chain (n=5). (A and B) Data were normalized to values obtained in the 
absence of Tim-3 blocking antibody. All experiments were performed in duplicate.  
	  





Our data indicate that following activation, Tim-3 functions as an inhibitory receptor in 
melanoma patients' NK cells by reducing their cytotoxicity and cytokine secretion potential. 
More importantly, these results demonstrate that Tim-3 blockade increases the expression of 
IL-2R, making NK cells more responsive to IL-2 stimulation, and consequently can enhance 
the function of NK cells from advanced melanoma patients. 
 
4.4. Discussion 
Our results demonstrate for the first time that exhausted NK cells upregulate Tim-3 which 
behaves as an inhibitory receptor/exhaustion marker, similarly to its role described for T cells. 
Furthermore, the levels of this receptor seem to be of key importance, since NK cells express 
Tim-3 in unstimulated conditions and upregulate this receptor when they become exhausted.  
Contradictory roles have been described for Tim-3 in NK cells from healthy donors. While 
one study showed that Tim-3 inhibits normal donor NK cell-mediated cytotoxicity132, the 
other suggested that Tim-3 may instead enhance IFN-γ production133. While the two studies 
are difficult to align, different model systems and contexts could explain these contradictory 
outcomes, as has been reported for other NK cell receptors such as 2B4 and KIR2DL4193,194. 
Our data are consistent with Tim-3 acting as an inhibitory receptor on NK cells from healthy, 
and most importantly, from melanoma donors. When triggered, we also show that it does not 
promote NK cell death. Rather, Tim-3 negatively regulates NK cell function in a Gal-9-
independent manner, suggesting a role of other Tim-3-ligands. PtdSer, a Tim-3 ligand, is 
exposed on the surface of apoptotic cells and may be a candidate for causing NK cell 
exhaustion in vivo after tumor cell death.  
Interestingly, when we blocked Tim-3 receptor with a soluble antibody, we were able to 
partially recover NK cell function. This reversal is comparable to that seen in T cells after in 
vitro blockade of another immune checkpoint such as PD-1 blockade92,195, that is now being 
used in clinical trials with impressive clinical responses61,62. The Tim-3 blocking antibody 
binds and internalizes the Tim-3 receptor, decreasing its expression on the membrane of NK 
cells and the possibility of binding to the natural ligands. Another possibility is that we are 
blocking the intrinsic inhibitory pathway of Tim-3, independently of any ligand. We also 
showed that Tim-3 blockade induces a 10% increase of CD16 expression (mean fluorescence 
	  





intensity - MFI), which could provide another explanation for the increase in NK cell 
function. Thus CD16, an activating receptor that is directly involved in the lysis of tumor 
cells, may function not only through ADCC but also independently of antibody binding. 
Finally, we demonstrated that Tim-3 blockade increases expression of the IL-2R on the 
membrane of MD NK cells, making them more responsive to IL-2 stimulation. The enhanced 
responsiveness may contribute towards the partial reversal of MD NK cell function after Tim-
3 blockade. 
Similarly to CTLA-4 and PD-1, Tim-3 belongs to the group of immune checkpoint molecules 
and is a potential therapeutic target. Although there is no clinical data available yet, it has 
been reported that Tim-3 is co-expressed with PD-1 on human tumor-specific CD8+ T cells, 
and that dual blockade of both molecules significantly enhances the in vitro proliferation and 
cytokine production of human T cells93. Furthermore, in vivo studies have shown that Tim-3 
blockade alone, or in combination with PD-1 blockade, is able to control tumor growth in four 
different tumor models, including melanoma123,124. A recent study showed that Tim-3 
blockade stimulates potent anti-tumor responses against established melanoma via NK cell-
dependent mechanisms when associated with a vaccine138. However, in those studies it was 
not clear if Tim-3 had a direct effect on NK cells. Our findings provide the first evidence that 
Tim-3 blockade can directly reverse NK cell exhaustion and improve the function of NK cells 
from melanoma patients. Even though the recovery of melanoma NK cell function is 
significant, it is not complete. Possibly, Tim-3 works along with other receptors to regulate 
NK cell exhaustion, although we could not detect a role for either CTLA-4 or PD-1. 
Nevertheless, combinatorial strategies that also target other inhibitory NK cell receptors could 
possibly recover NK cell phenotype more completely. Our study has direct clinical relevance 
since as shows for the first time that, by blocking Tim-3, it is possible to improve, ex vivo, the 
function of NK cells which could be used for NK cell adoptive transfer therapy. Moreover, 
our studies support the concept that systemic Tim-3 blockade could improve anti-tumor 
response in the context of melanoma, as is the case with systemic CTLA-4 and PD-1 
blockade. Less adverse events should be expected with Tim-3 blockade since Tim-3-deficient 
mice are viable and do not develop autoimmune or lymphoproliferative diseases119, as 
opposed to CTLA-4 deficient mice196.  
In conclusion, this study shows for the first time that Tim-3 is an exhaustion marker expressed 
on NK cells from advanced melanoma patients and that its blockade reverses their exhausted 
	  





phenotype. Tim-3, therefore, represents a promising therapeutic target that could enhance 




























CHAPTER 5:  
THE EFFECT OF IPILIMUMAB ON NK CELLS IDENTIFIES 
THE SUBSET OF ADVANCED MELANOMA PATIENTS 
WITH CLINICAL RESPONSE 
 
5.1. Introduction 
Metastatic melanoma is the deadliest and most aggressive form of skin cancer197. Current 
treatment strategies including surgery, chemotherapy, oncogenic kinase inhibitors, 
immunotherapy (ipilimumab), and/or radiation therapy have improved response rates and 
increased survival, however a broadly applicable curative therapy does not yet exist for this 
disease. Therefore, a better understanding of the current strategies for the treatment of 
melanoma is needed, in order to make them safer and more effective.  
Ipilimumab is a monoclonal antibody against CTLA-4 that prolongs overall survival in 
advanced melanoma patients, as was demonstrated in a randomized phase III study35, leading 
to its approval by the FDA. More impressive than the mean survival benefit was the effect of 
ipilimumab on long-term survival (3 years) in a subset of patients (≈20%)35,68. However, it 
has yet to be determined why this select group of patients respond, and what confers 
resistance198. 
CTLA-4 is an inhibitory receptor initially described in T cells, but that has recently also been 
shown to be present in monocytes and mature DCs103. Intracellular CTLA-4 is detectable only 
at low levels in naïve human T cells and, upon activation, this receptor is rapidly expressed on 
the cell surface. Tregs show high amounts of intracellular CTLA-4 and constitutively express 
this receptor at the cell surface104. CTLA-4 plays key role in controlling and dampening CD8+ 
T cells after they have received co-stimulatory signals. Besides playing a role in CD8+ T 
effector cells, CTLA-4 also seems to have an important role in the two major subsets of CD4+ 
T cells, though with distinct effects: downregulation of Th cells and enhancement of Tregs. 
The expression of CTLA-4 on NK cells is very low, and its role in these cells remains still 
unknown. Moreover, the effect of ipilimumab on NK cells, and its association with clinical 
	  





response to this treatment has not yet been evaluated.  
In this study we aimed to evaluate the effect of ipilimumab on the phenotype/function of NK 
cells from advanced melanoma patients, and to study how the effect of ipilimumab on NK 
cells from these patients relates to clinical response. 
 
5.2. Material and Methods 
Human samples: Blood samples were obtained under the Interdisciplinary Melanoma 
Cooperative Group IRB approved protocols (#H10362) from 10 advanced melanoma patients 
(stages III/IV) before and after treatment with ipilimumab (3mg/kg q3w). The study was 
approved by the Institutional Research Board at NYU in accord with a Federalwide 
Assurance approved by the Department of Health and Human Services. All patients provided 
informed written consent at the time of enrollment. 
Reagents, cell lines, NK cell purification and stimulation, cell staining and flow 
cytometry analysis, cytotoxicity, IFN-γ  production and proliferation assays were 
referenced in CHAPTER 2. 
Study design: NK cells were purified from the peripheral blood of 10 advanced melanoma 
patients treated with ipilimumab. Blood samples were collected at baseline, after cycle #2 and 
after cycle #4 of ipilimumab treatment. NK cells were characterized according to the 
expression of activating (NKG2D) and inhibitory (KIR3DL1) receptors, function 
(cytotoxicity and IFN-γ production), levels of IL-2Rα and response to IL-2 stimulation. We 













Statistical analyses: Separate analyses were performed for each experiment individually. 
Two tailed t tests were used. Analyses took into account paired observations within donors 
when appropriate, or unpaired observations when we compared parameters between 
responders and non-responders’ NK cells.  
 
5.3. Results 
The effect of ipilimumab on NK cells was studied in 10 advanced melanoma patients (Table 
5.1). We compared the phenotypic and functional profile from NK cells from these 10 
melanoma patients before treatment with ipilimumab (baseline) and after each cycle (cycles 
#2 and #4). Interestingly, ipilimumab induces an upregulation of IL-2R α chain in NK cells, 
with an increase in approximately 50% of the IL-2Rα levels (p=0.03) (Figure 5.2.A and 
5.2.B). There was no significant difference in the expression levels of other receptors or 
difference in function, including cytotoxicity and IFN-γ production (p>0.05).  
 
	  
Figure	  5.1.	  Scheme	  of	  the	  study	  design.	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We then assessed the phenotype and function of these NK cells after 48 hours of IL-2 
stimulation and observed that in 4 out of 10 patients there was an increase of cytotoxicity and 
Table 5.1. Demographic and clinical characteristics of 10 
advanced melanoma patients treated with ipilimumab. 











 NK cells before (baseline) and after treatment 
with ipilimumab (cycles #2 and #4). The (*) means p<0.05. (B) Graph showing the difference in percentage 
of CD25
+
 (α-chain) NK cells between before treatment and after the #4 cycle of ipilimumab. All 
experiments were performed in duplicate. 
	  





an increase in levels of IL-2Rα. Remarkably, this improved response to IL-2 was observed in 
patients with clinical response to ipilimumab, with partial (decrease of more than 30% of the 
tumor volume) or complete (disappearance of all target lesions) response, compared with non-
responders (progressive disease, with at least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study over the treatment). Therefore, 
partial/complete responders (PR/CR) display higher cytotoxic ability (p=0.05) (Figure 5.3.A) 







Figure 5.3. Responders to ipilimumab treatment have a better response to IL-2 stimulation. The plots 
display the difference between responders (PR/CR) and non-responders (NR) in the variation (unstimulated vs 
2-days of IL-2 stimulation) of the percentage of lamp-1
+
 (A) and CD25
+
 (B) cells. (C) Lamp-1 and (D) CD25 
expression on unstimulated and stimulated NK cells (from baseline and after #2 or #4 cycles of ipilimumab), 
from one representative responder (upper panel) and non-responder (lower panel) to the ipilimumab 
treatment. All experiments were performed in duplicate.  
	  






We have shown that ipilimumab induces an increase of IL-2R expression in NK cells, and 
consequently a better response to IL-2 stimulation and enhanced cytotoxicity. More 
important, this effect of ipilimumab on NK cells is associated with a good clinical response. 
The mechanism behind this effect is not clear yet; however some hypotheses can be 
considered. Even though the expression of CTLA-4 on NK cells is considerably low45,104, this 
effect could be a consequence of the direct blockade of the 1-3% of CTLA-4 positive cells. 
Another hypothesis is that CTLA-4 blockade on Tregs would inhibit their suppressive effect 
on NK cells. Indeed, there is new evidence showing that the mechanism of action of 
ipilimumab takes place through the inhibition of the immunossupressive effect of Tregs, that 
constitutively express CTLA-4 in higher levels199,200. Finally, patients treated with anti-
CTLA-4 antibody blockade generated high-titer anti-MICA antibodies that were associated 
with enhanced therapeutic efficacy by relieving immunosuppression and stimulating anti-
tumor cytotoxicity201. Unfortunately it was not possible to test this hypothesis in our cohort, 
and further investigation is needed. 
These intriguing and interesting results need to be confirmed in an independent cohort and 
more translational studies are needed to clarify the mechanism underlying this effect. 
Nevertheless, these data support the development of clinical trials to test the treatment 















CHAPTER 6:  
DISCUSSION 
 
T cell exhaustion has been described in different contexts, including chronic infectious 
diseases and different types of cancer92,93; however, our results provide the first demonstration 
that NK cells from advanced melanoma patients can also display the four main characteristics 
that define T cell exhaustion. Our study demonstrates that NK cells in the context of 
metastatic melanoma upregulate inhibitory receptors, while downregulating activating 
receptors and IL-2R, are less responsive to IL-2 stimulation, are functionally impaired 
(reduced cytotoxicity, cytokine production and proliferation) and express reduced levels of 
the transcription factors Eomes and T-bet. Differently from T cells, NK cells do not 
upregulate significantly the expression of CTLA-4 or PD-1. Interestingly, even though NK 
cells express Tim-3 in the steady state, the NK cell exhausted phenotype is characterized by 
an upregulation of this receptor. Therefore, the levels of Tim-3 in association with functional 
defects seem to be of key importance in defining Tim-3’s role in NK cell function.  
The concept of immune cell exhaustion originated from a T cell functional 
hyporesponsiveness associated with CD8+ T cells in the context of chronic viral infections. 
However, as previously mentioned, there are different types of functional hyporesponsiveness 
with distinct mechanisms that need to be discriminated. T cell exhaustion consists of a 
progressive loss of effector function as a consequence of persistent antigen and inflammation 
during chronic infection. In the context of self-ignorance, T cells are hyporesponsive due to 
antigen-inexperience. Central and peripheral tolerance is responsible for the deletion or 
inactivation of auto-reactive cells. T cell anergy is a result of stimulation without co-
stimulatory signals. Finally, senescence corresponds to an irreversible, permanent cell cycle 
arrest commonly reflected by telomere shortening (Hayflick limit)203. Looking more deeply 
into the process of T cell exhaustion, interestingly, it represents an adaptive state of 
hyporesponsiveness that, although insufficient to completely clear the pathogen, can provide 
the host with the ability to control the infection without causing detrimental immunological 
pathology. Therefore, it does not correspond to a fixed, irreversible, terminal differentiation 
state, nor an unresponsive T cell state, as has been shown by the development of clinical 
	  





responses with the blockade of exhaustion markers or commonly called immune checkpoints. 
Pre-clinical models113 and, more recently, clinical trials204 have shown that these immune 
checkpoints, including CTLA-4, PD-1, LAG-3, 2B4, and Tim-3 act via nonredundant 
signaling pathways to establish T cell exhaustion, thus having a synergistic role in this 
process. Therefore, T cell exhaustion is controlled and ‘tuned’ by the expression of the 
immune checkpoint ligands, besides several suppressive factors in the environment, including 
cytokines such as IL-10 and TGF-β, immune cells including MSDC205, Tregs90, and 
prolonged production of type I IFNs (IFN-α/β) that paradoxically upregulate expression and 
production of inhibitory molecules. This concept of T cell exhaustion has been translated into 
the oncology field based on the observation that T cells isolated from human tumors as well 
as experimental tumor models share many genomic, phenotypic and functional characteristics 
of exhausted T cells in chronic infections. Therefore, TILs are impaired in the production of 
effector cytokines, express inhibitory receptors including PD-1, LAG-3, 2B4, Tim-3, and 
CTLA-4, and display alterations in signaling pathways described for exhausted T 
cells92,206,207.  
For many years, functionally impaired NK cells have been observed and described in different 
types of cancer, including breast97, gastric208, lung209 and ovarian210 cancers. This NK cell 
dysfunction is characterized by decreased cytotoxic activity, downregulation of expression of 
activating receptor expression and intracellular signaling molecules, defective proliferation, 
poor infiltration, decreased cell counts, and defective cytokine production211. Nevertheless, 
several studies have suggested that these functionally impaired NK cells are a consequence of 
the absence of sufficient activating signals in the TME. Some publications have demonstrated 
the reversal of this tumor-associated NK cell phenotype after IL-2 stimulation172,173. In 
contrast, our data indicates that even after IL-2 stimulation, NK cells from melanoma patients 
have a dysfunctional phenotype compared with healthy donors. Therefore, it is not possible to 
reverse completely the NK cell exhausted phenotype, even through ex vivo activation.  
As previously shown in a tumor mice model98, our data suggest that NK cells become 
progressively exhausted through melanoma stages, making them a potential therapeutic target. 
Accordingly, NK cell infiltration in tumor tissue is associated with better prognosis95,175,176, 
while low activity of peripheral blood NK cells is associated with increased risk of cancer150. 
Different immunotherapeutic NK-cell based strategies have been developed, including 
cytokines that boost the NK cell response (IL-2, IL-21 or IL-15), adoptive NK cell transfer 
	  





and the blockade of inhibitory receptors. Several questions remain regarding the exact 
mechanism of T cell functional unresponsiveness in the context of cancer. Nevertheless, 
different hypotheses have been postulated, including: (i) cell-intrinsic self-tolerance programs 
imprinted in self/tumor antigen-specific T cells212; (ii) cell-intrinsic programs induced in 
tumor-specific T cells that encountered tumor antigen during the early or premalignant, 
noninflammatory phase of tumor development213,214; (iii) cell-intrinsic and extrinsic 
immunosuppressive factors in the TME including chronic tumor-antigen encounter, 
expression of inhibitory receptors and availability of their ligands, MSDC, Tregs, cytokines 
such as IL-10 and TGF-β, and compounds such as nitrate nitrogen (NOS), ROS, nitrogen 
species, and IDO; and/or (iv) physiological changes within tumors including hypoxia, low 
nutrient levels, low pH, and/or high interstitial fluid pressure. To our knowledge, the concept 
of NK cell exhaustion, by analogy with similar findings in CD8+ T cell biology215, was first 
described in 2012 by Gill and colleagues, in an adoptive NK cell transfer tumor mice model. 
The exact mechanism of NK cell exhaustion is still unclear; however, some hypotheses have 
been postulated. NK cells might become exhausted due to the inhibitory TME, which contains 
inhibitory cytokines (TGF-β, IL-10 and IDO) and cells (TAMs, Tregs, MSDCs)142. 
Furthermore, sMICA shed from tumor cells also inhibits NK cells’ cytotoxicicy157, and this 
functional impairment appears to correlate with elevated sMICA sera levels157. In this study 
we have shown that high levels of sMICA in the plasma are associated with shorter 
recurrence free survival and overall survival. Therefore, MICA may be an independent key 
independent prognostic factor in melanoma.  
Tim-3 has been reported to be expressed on activated CD4+ T cells, CD8+ T cells, monocytes, 
DCs and NK cells216, however a high expression of Tim-3 mRNA was observed in human NK 
cells when compared with other lymphocyte populations120. Two studies presented 
contraditory results regarding Tim-3 function in NK cells from healthy donors; while one 
showed that Tim-3 inhibits NK cell cytotoxicity132, the other demonstrated that Tim-3 
increases IFN-γ production when stimulated with Gal-9133. Contradictory roles have been 
similarly described for other NK cell receptors such as 2B4193 and KIR2DL4194. The Tim-3 
pathway was also described to influence NK cell function in patients with hepatitis B virus 
infection134 and atherogenesis217, in which upregulation of Tim-3 on NK cells correlates with 
decreased IFN-γ production and cytotoxicity. Moreover, Tim-3 plays a key role in 
maintaining the process of sepsis, through a negative regulation of the TLR4-mediated 
	  





immune responses128. In the context of LPS-induced endotoxic shock, Tim-3 acted as a 
marker of immune exhaustion and Tim-3-positive T cells and NK cells had a lower interferon 
(IFN)-γ production218,219. Our data are consistent with Tim-3 acting as an inhibitory receptor 
on NK cells from healthy, and most importantly, from melanoma donors. We demonstrate, for 
the first time, that Tim-3 behaves as an exhaustion marker on NK cells, similarly to its 
described role in T cells, and it negatively regulates NK cell function in a Gal-9-independent 
manner.  
Interestingly, when we blocked Tim-3 receptor with a soluble antibody we were able to 
recover, in part, NK cell function from melanoma patients. The Tim-3 blocking antibody 
binds and internalizes its receptor, decreasing its expression in the membrane of NK cells and 
the possibility of it binding to natural ligands, including Gal-9, HMGB1, CEACAM1 and 
phosphatidylserine. Gal-9 is characterized by β-galactoside binding affinity and the presence 
of an evolutionary conserved sequence, the carbohydrate recognition domain (CRD), that 
binds to specific carbohydrate moieties on glycoconjugates and is therefore able toto decode 
and interpret the glycome from the microenvironment220. The widespread localization of Gal-
9 implies that it exerts a large variety of functional roles, such in, angiogenesis, apoptosis221 
and T cell homeostasis222. Gal-9 inhibits T cell function, like proliferation, cytotoxicity and 
cytokine production, through a Tim-3 interaction223,224. Interestingly, galectins are 
increasingly recognized as prognostic markers for malignancies and galectin-9 is no exception 
to this225. When screening a panel of 84 breast tumors it was observed that, Gal-9 was 
expressed in half of these tumors and high Gal-9 expression resulted in an increased 
cumulative disease free survival of these patients226,227. In contrast, most current data suggest 
an inverse relation between Gal-9 expression and cancer progression for the majority of solid 
tumors. The association of a higher expression of Gal-9 with good prognosis may be 
explained by the pleiotropic functions of the glycoprotein. It is important to note that most 
studies did not take into account the extensive Gal-9 splicing. Therefore, it remains to be 
determined whether the expression of specific splice variants is also different in human tumor 
tissues228. Our study demonstrates that Gal-9 inhibits the immune system by binding to Tim-3 
on NK cells, which can contribute to tumor immune evasion.  
HMGB1 is a DNA chaperone that maintains nuclear homeostasis as well as an extracellular 
damage associated molecular pattern molecule (DAMP), that plays a significant role in many 
diseases, especially inflammatory diseases and cancer229. Cancer development is a multistep 
	  





process, and HMGB1 seems to contribute to each of these steps of cancer development. 
HMGB1 has paradoxically been reported to promote both cell survival and cell death by 
regulating multiple cancer signaling pathways230. While extra-cellular HMGB1 acts mainly as 
a protumor protein due to its cytokine, chemokine, and growth factor activity, intracellular 
HMGB1 acts as an antitumor protein due to its ability to sustain genome stability and 
autophagy activity during tumor growth231,229. Through the expression of pattern recognition 
receptors (PRRs), such as TLRs and receptor for advanced glycation endproducts (RAGE), 
which recognize DAMPs and pathogen-associated molecular patterns (PAMPs) released by 
stressed cells, DCs play an essential role in initiating innate immune responses against 
pathogens and tumors. In their recent paper, Chiba and coworkers showed that HMGB1 
specifically binds to Tim-3 on DCs’ surface and that this HMGB1/Tim-3 complex is then 
internalized into endosomal vesicles. This protein complex impedes HMGB-1-mediated 
recruitment of nucleic acids within the endosomes, leading to a decrease of the efficacy of 
immune responses to nucleic acids. Indeed, Tim-3 competes with nucleic acids to bind to the 
A box of HMGB1, impeding the HMGB1/DNA association, and thus blocking the activation 
of innate immune system. Thus, when HMGB1 binds to Tim-3 in tumor-associated DCs, the 
innate immune responses toward the tumor are blocked resulting in increased tumor 
expansion116.  
CEACAM1 is a member of the CEA-family of Ig-like transmembrane proteins that is 
expressed in a wide range of normal tissues and tumors232. Early studies have shown that 
CEACAM1 behaves as a tumor suppressor gene, since its expression is often lost in sporadic 
colorectal and prostate cancers in humans and, consistent with this, tumor size and number are 
increased in Ceacam1−/− mice exposed to azoxymethane administration233. Recent studies in a 
wide variety of human tumors, including melanoma, lung and colon cancer, have observed 
that high levels of CEACAM1 expression on tumor cells directly correlate with poor 
prognosis and tumor metastasis234,235,236. In a recent study, Huang and colleagues have shown 
that CEACAM1 serves as a heterophilic ligand for Tim-3 that is required for its ability to 
mediate T-cell inhibition, and that this interaction has a crucial role in regulating 
autoimmunity and anti-tumor immunity. Remarkably, co-blockade of CEACAM1 and Tim-3 
leads to enhancement of anti-tumor immune responses with improved elimination of tumors 
in mouse colorectal cancer models117.  
PtdSer is a negatively charged phospholipid located in the inner leaflet that is exposed on the 
	  





surface of cancerous and other pathological cells237, as well as apoptotic cells. In general, 
apoptotic cells exposing PtdSer in the outer leaflet of the plasma membrane are specifically 
recognized by macrophages238 and DCs239. Tim-3 expressing cells can respond to apoptotic 
cells through TIM-3/PtdSer binding, but the consequence of Tim-3 engagement of PtdSer 
depends on the polymorphic variants of and type of cell expressing Tim-3. Therefore, tumor 
cells may circumvent apoptosis and prevent recognition by macrophages through the Tim-3-
PtdSer pathway240.  
According to our data, other possible mechanisms of the reversal of NK cell exhaustion are: 
the blockade of the intrinsic inhibitory pathway of Tim-3 (independently of any ligand); an 
enhanced ADCC, due to higher CD16 expression; and a better response to IL-2 stimulation, 
as a consequence of higher IL-2R expression. Tim-3 belongs to the family of immune 
checkpoints and, like CTLA-4 and PD-1, is a potential therapeutic target. Several in vitro and 
in vivo studies have shown that Tim-3 blockade alone or in combination with PD-1 blockade 
translates into tumor growth control93,123. Our data demonstrate that Tim-3 blockade is able to 
revert, in part, the NK cell exhausted phenotype. This suggests that Tim-3 plays an important 
role in the process of exhaustion, along with other inhibitory receptors, supporting the 
combination of different immune checkpoint inhibitors. 
NK cells from advanced melanoma patients show an overexpression of Tim-3, displaying low 
expression of other exhaustion markers, such as PD-1 and CTLA-4. We studied the effect of 
ipilimumab on NK cells from 10 advanced melanoma patients. Interestingly, we have shown 
that ipilimumab induces an increase of IL-2R expression in NK cells, and consequently a 
better response to IL-2 stimulation and enhanced cytotoxicity. More importantly, this effect of 
ipilimumab on NK cells is associated with a good clinical response. The mechanism behind 
this effect is not clear; however some hypotheses can be suggested. Even though the 
expression of CTLA-4 is considerably low in unstimulated peripheral NK cells (1-3% of 
CTLA-4 positive cells), Stojanovic A et al recently demonstrated that both CD28/CTLA-4–
expressing NK cells and B7-1/2–expressing myeloid cells are present in the tissue of different 
tumors, making these NK cells potential therapeutic targets241. Another hypothesis is that 
blockade of CTLA-4 on Tregs that constitutively express this receptor in higher levels, 
inhibits their suppressive effect on other cells, including CD8+ and NK cells242. Finally, it has 
been demonstrated that patients treated with anti-CTLA-4 antibody blockade generated high-
titer anti-MICA antibodies, that are associated with a reduction of circulating sMICA and an 
	  





enhancement of NK cell and CD8+ T lymphocyte cytotoxicity, and consequently with a 
higher therapeutic efficacy201.   
Collectively, our findings show that NK cells in advanced melanoma patients display an 
exhausted phenotype that develops gradually beginning at stage I and advancing to stage IV. 
Furthermore, Tim-3 and KIR3DL1 are overexpressed while cytotoxicity and IFN-γ 
production are impaired in MD NK cells and their levels correlate with the thickness of 
primary lesion and presence of metastasis. More importantly, Tim-3 behaves as an inhibitory 
receptor in NK cells from advanced melanoma patients and through its blockade it is possible 






















CHAPTER 7:  
FINAL REMARKS AND FUTURE DIRECTIONS 
 
When I decided to study melanoma, there were only dacarbazine, temozolamide and a few 
more chemotherapeutic agentes were then available to treat advanced melanoma patients, 
with really poor clinical responses. At that time, immunotherapy was still a dream followed 
by some clinicians and researchers, with several past disappointing results. 
I joined the Bhardwaj laboratory in 2010 and Ipilimumab was approved by FDA for advanced 
melanoma the following year. In 2014, anti-PD-1 was approved not only for advanced 
melanoma, but also for lung cancer, and we all expect it to be approved for other tumor types. 
There is no doubt that immunotherapy is gaining its space and respect in the oncology field. 
The main targets of immunotherapy during these last years have been the DCs, regarding the 
vaccines, and T cells, through the use of immune checkpoint inhibitors. The aim of our 
project was to study the role of NK cells, the most relevant anti-tumor cells along with T 
cells, in the context of melanoma. Our goal was to characterize their phenotype and function 
through the different melanoma stages and investigate how to manipulate these cells in order 
to make them fight tumor cells more efficiently. Tim-3 is an immune checkpoint like CTLA-4 
and PD-1 on T cells, but with a controversial role in NK cells. Our goal was to check the role 
of Tim-3 in NK cells from advanced melanoma patients. 
This study demonstrated for the first time that NK cells acquire an exhaustion phenotype as 
melanoma progresses. However the mechanism underlying this process and pathways 
involved remain unclear. More translational studies are needed to clarify this phenomenon, in 
order to improve the available immunotherapeutic strategies and define new ones. 
Moreover, we have demonstrated that the expression of sMICA in the plasma is an 
independent prognostic factor and preditor of recurrence in melanoma patients. This finding 
will more accurately help define the group of patients that would benefit from adjuvant 
therapy. However, these results will need to be validated in other centres also. 
	  





We have found that Tim-3 clearly has an inhibitory function on NK cells from advanced 
melanoma patients, and its blockade reverses, partially, NK cell exhaustion. These findings 
may have major implications as Tim-3 becomes a potential therapeutic target. We clarify part 
of the mechanism of action of anti-Tim-3 mAb; however, a more detailed effect on NK cells 
and on other cells should be clearly defined. 
Finally, anti-CTLA-4 (ipilimumab) induces an upregulation of IL-2R in NK cells, making 
them more responsive to IL-2 stimulation. Some mechanisms of action of ipilimumab have 
been postulated, and each of them should be tested in a translational project. 
 
In summary, the results from our research led to the following original conclusions, which can 
be translated into the clinic: 
 
 
1. NK cells from melanoma patients acquire an exhausted phenotype with the advancement  
through stages, making them an appealing therapeutic target. This also suggests that it may be 
possible to intervene early in the course of tumor progression.  
2. sMICA is a potential marker of prognosis and predictor of recurrence in melanoma.  
sMICA expression in the plasma from melanoma patients offers the great advantage that it 
can be easily quantified by ELISA. 
3. Tim-3 is an exhaustion marker expressed in NK cells from advanced melanoma patients 
and its blockade reverses their exhausted phenotype. Our in vitro studies, together with some 
preclinical studies suggest that anti-Tim-3 is a good candidate to be included in clinical trials 
for advanced melanoma patients. 
4. Ipilimumab improves NK cell function (increasing IL-2R expression and making these 
cells more responsive to IL-2 stimulation) in those patients who respond to the treatment. 
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